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Pre-existing autoantibodies to type I IFNs underlie critical COVID-19 pneumonia 
in patients with autoimmune polyendocrine syndrome type 1 
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Abstract 
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune 
polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-
Abs), including circulating auto-Abs neutralizing most type-I interferons (IFNs). These auto-
Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 
pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven 
countries, aged between 8 and 48 years and infected with SARS-CoV-2 since February 2020. 
The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω, one had anti-
IFN-β, another anti-IFN-ε, but none had anti-IFN-κ. Strikingly, nineteen patients (86%) were 
hospitalized for COVID-19 pneumonia, including fifteen (68%) admitted to an intensive care 
unit, eleven (50%) who required mechanical ventilation, and four (19%) who died. 
Ambulatory disease in three patients (14%) was possibly accounted for by prior or early 
specific interventions. Pre-existing auto-Abs neutralizing type-I IFNs in APS-1 patients 
confer a very high risk of life-threatening COVID-19 pneumonia at any age.  
 
Short summary (40 words) 
 Patients with autoimmune polyendocrine syndrome type-1 (APS-1) have circulating 
auto-Abs neutralizing most type-I interferons. These auto-Abs can underlie life-threatening 
COVID-19 pneumonia in the general population. We report 22 APS-1 patients infected with 
SARS-CoV-2 including fifteen (68%) who developed life-threatening disease.  
 
Running title (50 characters max) 
Autoimmune polyendocrine syndrome type-1 and COVID-19 
 
Abbreviation list 
AIRE: Auto-immune regulator 
APS-1: Autoimmune polyendocrine syndrome type-1, 
APECED: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, 
IFNs: Interferons, 
MMR: Measles-mumps-rubella,  
CMC: Chronic mucocutaneous candidiasis 
YFV: Yellow fever virus,  
monoclonal antibody (mAb) 
intravenous immunoglobulin (IVIg) 
JAK: Janus Kinase 
ICU: Intensive Care Unit 
ALC: Absolute lymphocyte count,  
AST: Aspartate transaminase 
ECMO: Extracorporeal membrane oxygenation, 
p02: Partial pressure of oxygen,  
CT-scan: Computed tomography scan,  
mmHg: Millimetre of mercury,  
CRP: C-reactive protein, 
LDH: Lactate deshydrogenase, 
 ISG: Interferon stimulated gene 
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Introduction 
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic inborn 
error of immunity typically caused by biallelic deleterious variants of the autoimmune 
regulator gene (AIRE)
1-5
. Heterozygous variants can also underlie autosomal dominant forms
6
. 
Patients with APS-1 have defective central T-cell tolerance, leading to the thymic escape of 
auto-reactive T cells and the development, from early childhood, of a broad range of 
autoantibodies (auto-Abs) against various autoantigens, including endocrine and other tissue 
antigens and cytokines
7-12
. Among these anti-cytokine auto-Abs, neutralizing auto-Abs 
against IL-17A and IL-17F phenocopy inborn errors of IL-17A/F and underlie chronic 
mucocutaneous candidiasis (CMC)
13-15
. High mucosal concentrations of IFN- were also 
proposed to contribute to CMC
16
. Virtually all patients with APS-1 produce auto-Abs against 
type I IFNs, generally against the 13 individual IFN-α subtypes and IFN-ω
11,12,17-19
. These 
auto-Abs were long thought to be clinically silent. This was surprising, as these auto-Abs are 
neutralizing and type I IFNs are potent antiviral molecules, acting through both innate 
immunity (via their secretion by plasmacytoid dendritic cells and other leukocytes) and cell-
intrinsic immunity (in most cell types)
20-26
. Moreover, the essential role of type I IFNs in 
fending off viruses in humans was confirmed by the description of patients with autosomal 
recessive, complete IFNAR1 or IFNAR2 deficiency and adverse reactions to measles-mumps-
rubella (MMR) vaccine or yellow fever virus (YFV-17D) live-attenuated viral vaccine
27-29
, 
herpes simplex encephalitis
30
, or critical COVID-19 pneumonia
30-32
. Nevertheless, the viral 
phenotype of these patients is not as broad as initially predicted, as neatly illustrated by two 
IFNAR1-deficient adults (26 and 38 years old) who had never been hospitalized for severe 
viral disease until they were admitted for critical COVID-19 pneumonia
31
. 
In this context, we and others recently reported that three unrelated patients with APS-
1 had life-threatening COVID-19 pneumonia 
33,34
. These cases suggested that the auto-Abs 
neutralizing type I IFN were pathogenic and contributed to the discovery that they can also 
underlie life-threatening COVID-19 pneumonia in previously healthy individuals without 
APS-1, accounting for at least 10% of the cases in an international cohort of patients
33
. These 
auto-Abs were more frequent in men (95%) than women (5%), and in elderly patients with 
critical COVID-19, half of the patients with auto-Abs being over the age of 65 years
33
. These 
auto-Abs typically neutralized the 13 individual IFN-α, or IFN-ω, or both, but only rarely 
IFN-, -, and -. These findings were replicated in other cohorts
35-39
. Subjects with inborn 
errors of type I IFN immunity or neutralizing auto-Abs against type I IFN are, thus, at high 
risk of critical COVID-19 pneumonia, with impaired control of viral replication in the first 
few days of SARS-CoV-2 infection resulting in a secondary phase of pulmonary and systemic 
hyperinflammation
32
. Subjects with such auto-Abs are also at high risk of YFV-17D disease, 
with these antibodies accounting for three of the eight cases studied
40
. Interestingly, the three 
patients with YFV-17D disease had auto-Abs that neutralized both the 13 IFN-α and IFN-ω, 
and two also had auto-Abs against IFN-, these proportions being higher than those reported 
for COVID-19 patients. It is unknown whether patients with APS-1 have ever been 
vaccinated with YFV-17D. Following on from the brief description of three APS-1 patients 
with critical COVID-19 pneumonia, we report here the immunological and clinical features of 
22 patients with APS-1 during the course of SARS-CoV-2 infection.   
 
Results 
Baseline characteristics of the patients  
The 22 patients studied were aged 8 to 48 years at the time of infection with SARS-
CoV-2 (median: 24.5 years). Nine were male and 13 were female. Eight were children under 
the age of 16 years (Table 1). All had undergone vaccination according to the schedules in 
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force in their country of origin, including vaccination with the live attenuated MMR, with no 
overt adverse events, between the ages of one to two years. None of the patients had a 
previous history of severe viral infection, and only one had a history of pneumonia. The 22 
patients came from 21 unrelated families (two patients were siblings). The patients originated 
from and lived in England (n=1), France (n=5), Italy (n=1), Russia (n=11), Scotland (n=1), 
Sweden (n=1), and the United States of America (n=2). Twenty-one of the 22 patients had a 
typical clinical diagnosis of APS-1 (i.e., any two of the classic triad of manifestations: 
hypoparathyroidism, adrenal insufficiency, and CMC), with confirmation of the presence of 
homozygous or compound heterozygous loss-of function variants of AIRE in the 17 tested 
patients. One 16-year-old patient with biallelic loss-of-function AIRE mutations (p.R257X) 
presented only CMC. Twenty-one of the 22 patients had a history of severe tissue auto-
immunity, including hypoparathyroidism (n=20), adrenal insufficiency (n=20), hypogonadism 
(n=9), enteropathy (n=9), pernicious anemia (n=6), alopecia (n=6), autoimmune hepatitis 
(n=3), and vitiligo (n=3), and all but four had a history of CMC. One patient was on 
immunosuppressive treatment with the B cell-depleting monoclonal antibody (mAb) 
rituximab and monthly intravenous immunoglobulin (IVIg) substitution, another was on 
treatment with the JAK inhibitor ruxolitinib, a third patients was receiving treatment with the 
calcineurin inhibitor tacrolimus, and another two patients were on monthly IVIg treatment. 
Other treatments included endocrine replacement therapy (hydrocortisone and/or 
fludrocortisone, n=20; levothyroxine, n=5) and antifungal prophylaxis (fluconazole, n=8).  
 
Clinical, radiographic, and laboratory characteristics of COVID-19 infection in 
22 patients with APS-1, in chronological order 
 Patient 1 is a 32-year-old Italian woman with a history of the classic triad 
manifestations, enteropathy and pernicious anemia
34
. She was diagnosed with bilateral 
COVID-19 pneumonia in February 2020 and hospitalized for 37 days in Northern Italy. She 
developed hypoxemia requiring ICU admission and mechanical ventilation for six days. She 
developed secondary pneumococcal pneumonia and sepsis-induced ventricular dysfunction. 
She was treated with corticosteroids and broad-spectrum antibiotics. Two months after 
discharge from hospital, her pulmonary function was persistently impaired (i.e., diffusing 
capacity for carbon monoxide, 55%).  
Patient 2 is a 35-year-old Scottish woman with a history of hypoparathyroidism, 
adrenal insufficiency and hypogonadism, but not CMC
33
. She was diagnosed with bilateral 
COVID-19 pneumonia in March 2020 and hospitalized for 12 days. She developed 
hypoxemia and was intubated and mechanically ventilated in the ICU for five days. She 
developed lymphopenia (ALC, 600/mm
3
) and a mild increase in transaminase levels (AST, 89 
U/L). She was treated with corticosteroids; she recovered and was discharged home.  
Patient 3 is a 48-year-old American woman of Danish ancestry with a history of the 
classic triad manifestations, hypogonadism, hypothyroidism, and Sjögren’s syndrome
33
. She 
was diagnosed with bilateral COVID-19 pneumonia and hospitalized in March 2020 for 17 
days. She developed hypoxemia and was intubated in the ICU for 11 days. She developed 
lymphopenia (ALC, 650/mm
3
), an increase in transaminase levels (AST, 1668 U/L), 
hyperferritinemia (14,679 g/dL), and high D-dimer levels. She was treated with 
corticosteroids and broad-spectrum antibiotics; she recovered and was discharged home. 
Patient 4 is a 21-year-old French man with a history of the classic triad manifestations, 
type 1 diabetes, asplenia, and myocarditis
14
. He was on monthly IVIg substitution at the time 
of infection. He developed a high fever and mild respiratory symptoms in May 2020. He was 
hospitalized, with radiographic evidence of mild pneumonia not requiring oxygen therapy.  
Patient 5 is a 34-year-old Russian man with a history of hypoparathyroidism, adrenal 
insufficiency, and enteropathy, but no CMC. He was hospitalized for 10 days in January 2021 
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with bilateral COVID-19 pneumonia. He developed hypoxemia requiring oxygen 
supplementation, lymphopenia (ALC, 380/mm
3
) and an increase in D-dimer levels. He 
received corticosteroids, tocilizumab, and broad-spectrum antibiotics, and made a full 
recovery.  
Patient 6 is a 13-year-old Russian girl with a history of the classic triad manifestations, 
autoimmune hepatitis, and enteropathy. She was diagnosed with COVID-19 infection while 
asymptomatic during a SARS-CoV-2 PCR test performed for screening purposes before a 
routine clinic visit in July 2020. Interestingly, she had been on rituximab since October 2017, 
and was also receiving IVIg substitution (0.5 g/kg monthly).  
Patient 7 was a 28-year-old Russian man with a history of the classic triad 
manifestations, enteropathy, and alopecia, who was hospitalized in the ICU for bilateral 
COVID-19 pneumonia in October 2020. He suffered severe hypoxemia requiring mechanical 
ventilation for four weeks, complicated by secondary bacterial sepsis, acute renal failure 
requiring hemodialysis, and two episodes of pneumothorax. He developed lymphopenia 
(ALC, 100/mm
3
), high transaminase levels (ALT, 225 U/L), and high D-dimer levels. He was 
treated with broad-spectrum antibiotics, with the initiation of corticosteroids and tofacitinib 
three to eight days after the onset of hypoxemia. He died after 47 days in the hospital. 
Patient 8 was a 32-year-old Russian woman with a history of the classic triad 
manifestations, autoimmune hepatitis, alopecia and a previous episode of pneumonia, which 
is seen in the setting of autoimmune pneumonitis in APS-1 patients
41
. She was hospitalized in 
the ICU of a hospital for COVID-19 for 15 days in October 2020. She developed severe 
hypoxemia requiring mechanical ventilation, and died of respiratory failure. She was treated 
with corticosteroids from day 13 of hospitalization, two days before her death. 
Patient 9 is a 14-year-old Russian adolescent with a history of CMC, adrenal 
insufficiency, alopecia and type 1 diabetes. He was hospitalized for bilateral COVID-19 
pneumonia for 15 days in October 2020. He developed hypoxemia requiring oxygen 
supplementation by a nasal cannula for six days. He recovered and was discharged home.  
Patient 10 is an eight-year-old Russian girl with a history of the classic triad 
manifestations, enteropathy, autoimmune hepatitis and autoimmune encephalitis. She was 
receiving IVIg substitution (0.5 g/kg monthly) at the time of infection. She was diagnosed 
with asymptomatic COVID-19 following screening by serological SARS-CoV-2 IgG testing 
after her mother was diagnosed with mild COVID-19 infection.  
Patient 11 is a 28-year-old Russian woman with a history of CMC, 
hypoparathyroidism, and enteropathy. She was hospitalized in October 2020 for 12 days for 
bilateral COVID-19 pneumonia not requiring oxygen supplementation. She developed 
lymphopenia (ALC, 190/mm
3
). She recovered and was discharged home.  
Patient 12 is a 16-year-old Russian man with a history of CMC and enamel 
hypoplasia. He was hospitalized for 26 days in October 2020 for bilateral COVID-19 
pneumonia. He developed hypoxemia requiring ICU admission and mechanical ventilation. 
He developed lymphopenia (ALC, 600/mm
3
) and his D-dimer levels increased. He was 
treated with corticosteroids, tocilizumab, and broad-spectrum antibiotics. He recovered and 
was discharged home.  
Patient 13 was a 20-year-old Russian woman with a history of the classic triad 
manifestations and hypothyroidism. She was hospitalized for 14 days for COVID-19 
pneumonia. She was already hypoxemic at admission and her hospital course was further 
complicated by worsening hypoxemia, requiring ICU admission and mechanical ventilation 
on day 9 of hospitalization. She was then treated with corticosteroids and tocilizumab, but 
died from respiratory failure five days after intubation.  
Patient 14 is a 31-year-old French woman with a history of the classic triad 
manifestations, hypogonadism, and pernicious anemia. She was hospitalized for more than 60 
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days for COVID-19 pneumonia in November 2020. She developed hypoxemia requiring ICU 
admission, mechanical ventilation, and extracorporeal membrane oxygenation (ECMO). She 
suffered from multiple secondary bacterial infections, including pneumonia, bacteremia, and 
sepsis, and ventricular tachycardia. She developed mild increases in transaminase (AST, 77 
U/L) and D-dimer levels. She was treated with corticosteroids. She survived but required 
tracheostomy and intensive respiratory rehabilitation due to persistent respiratory 
insufficiency.  
Patient 15 is a 45-year-old American man of Danish ancestry, brother of Patient 3, 
with a history of the classic triad manifestations, enteropathy, alopecia, pernicious anemia, 
hypothyroidism, and end-stage renal disease on hemodialysis. He was hospitalized in 
November 2020 as a prophylactic measure, to facilitate close monitoring after his diagnosis 
with COVID-19 at an external facility. He was febrile upon admission, with mild respiratory 
symptoms, no hypoxemia, and bilateral pneumonia on imaging. He was treated with 
remdesivir and corticosteroids, while ruxolitinib was continued to prevent progression to 
hypoxemia and rebound inflammation. His hospital course was complicated by pulmonary 
embolism (Fig. S1B), which was treated with anticoagulation. He recovered without needing 
oxygen supplementation or ICU admission and was discharged home after an 18-day stay in 
hospital.  
Patient 16 was a 38-year-old French woman with a history of the classic triad 
manifestations, hypogonadism, pernicious anemia, myocarditis, and cutaneous lupus. She was 
hospitalized for 13 days in November 2020. She developed hypoxemia requiring ICU 
admission and mechanical ventilation. She developed multiple bacterial superinfections and 
pneumothorax. She was treated with corticosteroids after intubation. She developed 
lymphopenia (ALC, 290/mm
3
), and her transaminase (AST, 76 U/L) and D-dimer levels 
increased slightly. She died of respiratory failure after 12 days of intubation.  
Patient 17 is an eight-year-old Swedish girl with a history of hypoparathyroidism, 
adrenal insufficiency, and vitiligo, but not CMC. She was hospitalized for bilateral COVID-
19 pneumonia at the end of November 2020. She developed hypoxemia requiring ICU 
admission and mechanical ventilation for four days. She was treated with corticosteroids, 
plasmapheresis, which successfully decreased type I IFN auto-Ab titers (Fig. 1C), and IVIg 
substitution. She recovered and was discharged home after a 20-day stay in hospital.  
Patient 18 is an 11-year-old French boy with the classic triad manifestations and 
hypothyroidism. He was hospitalized for 56 days in December 2020 for bilateral COVID-19 
pneumonia. His course was complicated by hypoxemia requiring ICU admission and 
mechanical ventilation. He developed lymphopenia (ALC, 300/mm
3
) and increases in D-
dimer and transaminase (AST, 48 U/L) levels. He was receiving tacrolimus before COVID-
19. He was treated with corticosteroids, IFN-β (45 μg, AVONEX, 3 injections), convalescent 
plasma, and plasmapheresis, which decreased type I IFN auto-Ab titers (Fig. 1D).  
Patient 19 is an 18-year-old British man with a history of the classic triad 
manifestations, hypogonadism, type 1 diabetes, and alopecia. He was diagnosed with 
COVID-19 infection at the end of December 2020 after the diagnosis of his parents. He 
developed a high fever and mild cough and was instructed to initiate stress-dose corticosteroid 
treatment and to continue until the symptoms had completely resolved, to prevent secondary 
hyperinflammation. He remained at home without the need for hospitalization and recovered 
after seven days. 
Patient 20 is a 15-year-old French girl with a history of the hypoparathyroidism, 
adrenal insufficiency, and hypogonadism, hypogonadism and retinitis. She had weekly 
methotrexate treatment for her retinitis. She was diagnosed with mild COVID-19 pneumonia 
in early January 2021. She had radiological evidence of bilateral COVID-19 pneumonia (Fig. 
S1C). After multidisciplinary discussion, she was hospitalized for treatment with three 
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injections of IFN- (45 μg, AVONEX) and convalescent plasma therapy to prevent 
progression to hypoxemic COVID-19 pneumonia. She developed high fever for 72h and 
recovered without requiring oxygen supplementation and was discharged home.  
Patient 21 is a 10-year-old Russian boy with a history of the classic triad 
manifestations, enteropathy, and retinitis. He was hospitalized for 24 days in January 2021 for 
bilateral COVID-19 pneumonia. He developed hypoxemia requiring oxygen supplementation 
by nasal cannula. He developed lymphopenia (ALC, 840/mm
3
) and his D-dimer levels 
increased. He was treated with corticosteroids, tocilizumab, prophylactic anticoagulation, and 
broad-spectrum antibiotics. He recovered and was discharged home. 
Patient 22 is a 30-year-old Russian woman with a history of hypoparathyroidism, 
adrenal insufficiency, and hypogonadism. She was hospitalized for six days in January 2021 
for COVID-19 pneumonia. She developed hypoxemia requiring oxygen supplementation by a 
nasal cannula. She presented a mild increase in transaminase levels (ALT, 128 U/L). She 
received corticosteroids, tofacitinib, faripiravir, and prophylactic anticoagulation. She 
recovered and was discharged home. 
 
Auto-Abs against type I IFNs in the patients 
All the patients tested (n=21, P6 not tested) had high titers of neutralizing auto-Abs 
against IFN-α2 and/or IFN-ω, and one (P3) also had auto-Abs against IFN- (Table 1). All 
patients but 2 had been tested for the auto-Abs before COVID-19 pandemic. We also tested 
for the presence of auto-Abs against the 17 individual type I IFNs for all patients for whom 
serum or plasma samples were available. Eight patients were tested for the presence of auto-
Abs against all 13 individual IFN-α and IFN-ω, and they all tested positive (Figure 1A). Only 
one patient had auto-Abs against IFN-β and one other had auto-Abs against IFN-ε while none 
of the patients tested had auto-Abs against IFN-κ. We then confirmed that these auto-Abs had 
neutralizing activity (Fig. 1B), against IFN-α2 and IFN-ω in all patients, and against IFN-β in 
the only patient positive for auto-Abs against this cytokine. We could not test the neutralizing 
activity of the auto-Abs to IFN-ε. The serum and plasma samples from patients without 
detectable auto-Abs against IFN-β did not neutralize the activity of this cytokine. Pre- and 
post-COVID serum samples were available for 4 patients, and we found no significant 
differences in titer or neutralization capacity of anti-IFN auto-Abs before and after SARS-
CoV-2 infection. We also tested for lung-targeted auto-Abs against the lung antigens KCNRG 
and BPIFB1 in 8 patients (5 severe and 3 mild/moderate)
41
. All examined patients were 
negative for KCNRG auto-Abs but two patients, one with severe (P17) and another with mild 
COVID-19 (P19), tested positive for BPIFB1 auto-Abs (Fig. S2).  
 
Life-threatening COVID-19 pneumonia in 15 APS-1 patients 
All 15 patients with hypoxemic COVID-19 pneumonia had positive SARS-CoV-2 
PCR results. They had a median age of 30 years (range: 8-48 years). Six were male and nine 
were female (Tables 1 and 2). Five were children under the age of 16 years. The patients were 
admitted to hospital between 2 and 10 days after the onset of clinical manifestations (median: 
5 days) and were hospitalized for a median of 16 days (range: 6-50 days). We applied the NIH 
ordinal scale (range: 1-8)
42
 to assess the severity of COVID-19 in these patients. They were 
found to have a median ordinal scale score of 7 (range: 5-8). The degree of hypoxemia was 
variable, with a median nadir pO2 of 82 mmHg (range: 60-93 mmHg). Eleven patients 
required intubation and mechanical ventilation for a median of six days (range: 1-27 days), 
and one patient required ECMO for 42 days. All patients had a chest CT-scan or X ray 
showing extensive bilateral ground-glass opacities due to severe COVID-19 pneumonia (Fig. 
S1A). Four patients suffered from bacterial superinfections, including ventilator-associated 
pneumonia, bacteremia, and sepsis. Two patients developed pneumothorax requiring chest 
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tube placement, twice in one patient, and ventricular tachycardia and sepsis-induced 
cardiomyopathy occurred in one patient each. One patient was discharged with a 
tracheostomy. All patients had high CRP levels, eight had lymphopenia, seven had high D-
dimer levels, six had high transaminase levels, and four had high ferritin and LDH levels.  
 
Managements of the 15 patients with life threatening COVID-19 
Thirteen patients received high-dose corticosteroids (>0.5 mg/kg prednisone 
equivalent/day) in the form of dexamethasone, betamethasone, hydrocortisone, 
methylprednisolone, or prednisone (Table 2); all 10 patients given corticosteroids within 24 
hours of the onset of hypoxemia survived, whereas all four patients receiving corticosteroids 
later in the course of their hypoxemic disease died (P=0.002; chi-squared test with Yates' 
correction). Six patients received broad-spectrum antibacterial antibiotics and three patients 
received antiviral treatment with faripiravir, ribavirin, or a combination of lopinavir/ritonavir 
with ribavirin. Four patients received anti-IL-6 receptor therapy (tocilizumab) and two 
patients received the JAK-inhibitor tofacitinib. One patient (P20) received convalescent 
plasma (twice, 24 hours apart) and intramuscular recombinant IFN-β (Avonex, 45 μg every 
48 hours, three injections). Plasmapheresis was performed in two patients (daily, five times 
for P17 and six times for P18), resulting in a decrease in type I IFN auto-Ab titers in both 
(Fig. 1C, D). One patient (P18) also received 3 injections of intramuscular IFN-β as well as 
convalescent plasma, after the first three plasmapheresis sessions. We monitored the blood 
interferon stimulated gene (ISG) response in this patient using Nanostring. Interestingly, we 
found a clear increase of ISGs after the initiation of plasmapheresis and IFN-β treatment (Fig. 
1D and S3). Four patients (18%) died from sepsis and/or respiratory failure. All the patients 
who died were adults (aged 20, 28, 32 and 38 years old). The 11 survivors, aged 8 to 48 years, 
have been discharged from hospital, including one patient suffering from chronic respiratory 
failure and still dependent on oxygen therapy at most recent follow-up. 
 
Mild non-hypoxemic COVID-19 infection in seven APS-1 patients and the 
efficacy of early treatment in three of these patients  
Seven of 22 patients (32%) had SARS-CoV-2 infection without developing 
hypoxemia (Tables 1 and 2). The median age of these patients was 18 years (range: 8-45 
years). Three were male and four were female. Three were children under the age of 15 years. 
Interestingly, two of these patients were receiving monthly IVIg therapy at the time of 
infection; one remained asymptomatic and was treated as an outpatient whereas the other was 
hospitalized with a high fever and bilateral pneumonia but did not develop hypoxemia. 
Another patient with asymptomatic infection was receiving IVIg and had also received 
rituximab eight months before the diagnosis of COVID-19. Moreover, an American man on 
ruxolitinib treatment was admitted for prophylactic monitoring when he developed a high 
fever and pneumonia. Treatment with corticosteroids and a 10-day course of remdesivir were 
initiated in this patient, with the aim of preventing progression to hypoxemic COVID-19. In 
addition, a British patient harboring BPIFB1 auto-Abs recovered at home following the early 
initiation and prolonged administration of stress-dose corticosteroid therapy after the 
development of a high fever with symptoms of pneumonia. Finally, a French patient whose 
family was made aware of the risk of severe COVID-19 in APS-1 was hospitalized 
prophylactically two days after symptom onset, while presenting mild radiographic lesions on 
a chest CT scan (Fig. S1C). She was treated with subcutaneous recombinant IFN-β (Avonex, 
45 μg dose every 48 hours, 3 doses) and convalescent plasma therapy for two consecutive 
days, with the goal of preventing progression to hypoxemic COVID-19. She recovered fully 
without the need for oxygen supplementation and was discharged home without sequelae.  
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Pre-existing auto-Abs to type I IFNs underlie life-threatening COVID-19 in APS-
1 patients 
We describe 22 patients with APS-1 from 21 kindreds from seven countries who were 
infected with SARS-CoV-2 between February 2020 and January 2021. Nineteen patients 
(86%) were hospitalized; 15 (68%) developed life-threatening bilateral COVID-19 
pneumonia with hypoxemia requiring admission to an ICU, 11 of whom required mechanical 
ventilation, including five who developed life-threatening secondary complications such as 
sepsis, pneumothorax, arrhythmias and/or pulmonary embolism, and four of whom died 
(18%). As we do not know how many SARS-CoV-2-infected APS-1 patients there are 
worldwide and our series probably reflects an ascertainment bias, we cannot rigorously 
estimate the proportion of life-threatening cases. However, our findings strongly suggest that 
APS-1 patients are at very high risk of critical COVID-19 pneumonia. Our previous report of 
auto-Abs against type I IFNs in at least 10% of patients with critical COVID-19 pneumonia, 
and in none of the subjects with asymptomatic or benign SARS-CoV-2 infection tested
33
 
further suggests that APS-1 patients are at high risk of developing critical disease because of 
their neutralizing auto-Abs against type I IFNs. This very poor outcome seems to be 
independent of age, sex, European ancestry, and the nature of any other autoimmune 
manifestations. Importantly, our findings confirm that auto-Abs neutralizing type I IFNs 
present before SARS-CoV-2 infection, as opposed to other auto-Abs potentially triggered by 
this infection, confer a very high risk of critical COVID-19
31,33,36-39
. We also found similar 
levels of auto-Abs prior to and after COVID-19 in the patients tested, further suggesting that 
the infection does not significantly trigger their production.  
 
Vaccination or early treatment to avoid life-threatening COVID-19 pneumonia  
Patients with APS-1 should be prioritized for vaccination against COVID-19. In the 
meantime, all necessary measures should be taken to avoid infection. Our report of seven 
patients with SARS-CoV-2 infection following a mild or moderate, non-hypoxemic course is 
of interest in this respect. Three of these seven patients were on monthly IVIg treatment, 
which may have decreased the pathogenicity of the auto-Abs against type I IFNs or acted 
through other mechanisms. Consistently, one of these patients was also receiving rituximab at 
the time of COVID-19 diagnosis, which may have altered the nature or decreased the titer of 
auto-Abs against type I IFNs. In addition, three patients whose medical teams had been 
informed by us of the risk of critical COVID-19 were treated early in the course of infection, 
one with an early and prolonged course of stress-dose corticosteroids, another by prophylactic 
admission with the administration of corticosteroids and remdesivir, and the third by early 
administration of subcutaneous IFN-. We thus recommend that infected patients should be 
hospitalized promptly. In patients diagnosed early, ideally before the development of 
pneumonia, several treatments may be considered. First, cocktails of mAb against the SARS-
CoV-2 spike protein may be given to accelerate the decline in viral load
43,44
; these antibodies 
should be preferred over convalescent plasma, the composition of which is unknown, and 
which may also contain auto-Abs against type I IFNs or other detrimental components and 
have not shown efficacy in severe COVID-19 pneumonia
45
. Intramuscular or nebulized IFN-
β, or subcutaneous pegylated-IFN-β, may also be considered in patients without auto-Abs 
against IFN-β
46
, as successfully reported for intramuscular IFN-2 in patients with inborn 
errors of type I IFN
47
 and for IFN-β in a patient with incontinentia pigmenti and auto-Abs 
against type I IFNs
48
. Obviously, the administration of IFN-2 is not indicated in APS-1 
patients. In patients treated with IFN-β, a monitoring of anti-IFN-β auto-Abs will be 
important. In the small minority of APS-1 patients carrying auto-Abs against IFN-β, 
alternative options could be considered.  
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Rescue treatment in patients with APS-1 and life-threatening COVID-19 
When patients present with hypoxemia in the later phase of COVID-19, the 
administration of mAbs against the SARS-CoV-2 spike protein and of IFN-β should be 
avoided, given the potential risk of worsening the hyperinflammation and hypoxemia
49,50
. In 
hypoxemic patients, the early initiation of high-dose corticosteroid treatment is crucial, to 
prevent a worsening of lung injury and death, as suggested by the observation that patients 
receiving high-dose corticosteroids at or within 24 hours of the onset of hypoxemia recovered, 
whereas the later initiation of corticosteroids was associated with death 
51
. Indeed, two 
symptomatic patients without hypoxemic disease who received corticosteroids did not 
progress to severe disease, further suggesting that early corticosteroid treatment might prevent 
or attenuate the secondary hyperinflammatory phase of disease
32
. The prompt initiation of 
corticosteroid treatment is of particular importance in APS-1 patients with pre-existing 
autoimmune pneumonitis, a frequently overlooked manifestation of APS-1 that affects up to 
~40% of patients
41
, as the inflammation-prone lung tissue in these patients may confer a 
predisposition to a worsening of lung injury. Two of the eight patients tested here had auto-
Abs against the lung auto-Ab BPIFB1. Such patients are often misdiagnosed as having a prior 
history of reactive airway disease or recurrent pneumonia
41
. Finally, both in the early phase of 
disease and after the development of COVID-19 pneumonia, plasmapheresis should be 
considered, as it has been safely performed in two APS-1 patients (this report) and four 
patients without APS-1
38
. This procedure can lower the titers of circulating auto-Abs against 
type I IFNs without lowering the titers of anti-viral Abs
38
, and it may be more beneficial when 
performed early in the course of hospitalization.  
 
 No previous viral disease before severe COVID-19  
 None of the 22 APS-1 patients had previously suffered from severe viral infections, 
consistent with the history of most patients with APS-1
10
. By inference from our recent 
observation that auto-Abs against type I IFNs can underlie life-threatening disease due to the 
YFV-17D live attenuated virus vaccine
40
, APS-1 patients should not be vaccinated against 
YFV. None of the 22 patients described here reported having been inoculated with the YFV-
17D vaccine. It is striking that these and other APS-1 patients have not been reported to suffer 
from other severe viral infections, including MMR disease and herpes simplex virus 
encephalitis, which have been reported in patients with IFNAR1 or IFNAR2 deficiency
27-30
. 
This may reflect the residual activity of some of the 17 type I IFNs, including IFN-β in 
particular, or that at the age of vaccination or HSV-1 infection, the auto-Abs were not yet 
present, or not as potent, or did not target all the type I IFNs neutralized in older APS-1 
patients. There is, nevertheless, one case report of an APS-1 patient suffering from recurrent 
cutaneous HSV-1 infection
52
. The paucity of viral infections in patients with inherited 
IFNAR1 or IFNAR2 deficiency is, itself, intriguing
27,28,30,32,53
. Careful retrospective and 
prospective studies of viral infections and viral diseases in APS-1 patients are therefore 
warranted. More generally, a careful study of viral infections and viral diseases in patients 
with inherited IFNAR1 or IFNAR2 deficiency, and in patients with auto-Abs against type I 
IFNs, regardless of their etiology, is also warranted.  
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Methods  
Patients and study approval 
Written informed consent was obtained from patients or their parents in the country in which 
they were followed, in accordance with local regulations. The study was approved by the 
institutional review boards of The Rockefeller University and Institut National de la Santé et 
de la Recherche Médicale (INSERM), the NIAID/NIH, the Endocrinology Research Center 
of Russia, and the University of Gothenburg, Sweden. Experiments were conducted in the 
United States of America and France, in accordance with local regulations and with the 
approval of the institutional review boards of The Rockefeller University, NIAID/NIH and 
INSERM. Anonymized samples were studied at the NIAID under non-human subject research 
conditions; no additional IRB consent was required at the NIH. APS-1 patients gave consent 
under IRB-approved protocols 11-I-0187 (clinicaltrials.gov NCT01386437) at the 
NIAID/NIH, study no 779-11. The Swedish patient was enrolled in study no 779-11, 
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approved by the Central Ethical Review Board at the University of Gothenburg. The study 
has been approved by the local ethics committee at Endocrinology Research Center of Russia 
(Protocol №11 from 23.10.2013) and all patients or their parents or guardians singed the 
informed consent. 
 
Detection of anti-cytokine auto-Abs using a cell-based assay 
All Russian patients were tested for neutralizing auto-Abs against IFN-α2 and/or IFN-ω using 
a cell-based assay as previously described
12,54
.  
 
Detection of anti-cytokine auto-Abs in a multiplex particle-based assay  
Serum/plasma samples were screened for auto-Abs against IFN-α2 and IFN-ω targets in a 
multiplex particle-based assay, in which magnetic beads with differential fluorescence were 
covalently coupled to recombinant human proteins (2.5 µg/reaction). Beads were combined 
and incubated with 1:100 diluted serum/plasma samples for 30 minutes. Each sample was 
tested once. The beads were then washed and incubated with PE-labeled goat anti-human IgG 
antibody (1 µg/mL) for 30 minutes. They were washed again and used in a multiplex assay 
run on a BioPlex X200 instrument. Patients with a fluorescence intensity (FI) > 1500 for IFN-
α2 or IFN-β, or > 1000 for IFN-ω were tested for blocking activity. 
 
Enzyme-linked immunosorbent assays (ELISA) for anti-cytokine auto-Abs 
ELISA was performed as previously described
33
. In brief, 96-well ELISA plates (MaxiSorp; 
Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 μg/mL rhIFN-α, 
and rhIFN-ω (R&D Systems). Plates were then washed (PBS/0.005% Tween), blocked by 
incubation with 5% nonfat milk powder in the same buffer, washed, and incubated with 1:50 
dilutions of plasma from the patients or controls for 2 h at room temperature (or with specific 
mAbs as positive controls). Each sample was tested once. Plates were thoroughly washed. 
Horseradish peroxidase (HRP)–conjugated Fc-specific IgG fractions from polyclonal goat 
antiserum against human IgG or IgA (Nordic Immunological Laboratories) were added to a 
final concentration of 2 μg/mL. Plates were incubated for 1 h at room temperature and 
washed. Substrate was added and the optical density (OD) was measured. A similar protocol 
was used to test for antibodies against 12 subtypes of IFN-α, except that the plates were 
coated with cytokines from PBL Assay Science (catalog #11002-1).  
 
Functional evaluation of anti-cytokine auto-Abs 
The blocking activity of auto-Abs against IFN-α2 and IFN-ω was assessed by evaluating 
STAT1 phosphorylation in healthy control cells following stimulation with the appropriate 
cytokines in the presence of 10% serum/plasma from a healthy control or a patient. Surface-
stained healthy control PBMCs (350,000/reaction) were cultured in serum-free RPMI medium 
supplemented with 10% healthy control or patient serum/plasma and were either left 
unstimulated or were stimulated with IFN-α2 and IFN-ω (10 ng/mL) for 15 minutes at 37°C. 
Each sample was tested once. Cells were fixed, permeabilized, and stained for intranuclear 
phospho-STAT1 (Y701). Cells were acquired on a BD LSRFortessa cytometer with gating on 
CD14
+
 monocytes and analyzed with FlowJo software. 
 
Luciferase immunoprecipitation systems (LIPS) assay for lung-targeted auto-Abs 
We used the LIPS immunoassay to detect auto-Ab immunoreactivity against the lung 
targeting the potassium regulator KCNRG and bactericidal/permeability-increasing fold-
containing B1 (BPIFB1) in APS-1 patient sera. Seropositivity was defined as a value greater 
than the mean for healthy donors plus three standard deviations, as previously described
41
. 
 
 14 
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Total RNA was extracted from whole blood with a PAXgene (PreAnalytix) RNA isolation 
kit. RNA concentration was assessed with a spectrophotometer (FLUOstar Omega, Labtech). 
Analysis of 24 genes and 3 housekeeping genes was conducted using the NanoString 
customer designed CodeSets according to the manufacturer’s recommendations (NanoString 
Technologies, Seattle, WA). Agilent Tapestation was used to assess the quality of the RNA. 
100ng of total RNA was loaded for each sample. Data were processed with nSolver software 
(NanoString Technologies Seattle, WA). The data was normalized relative to the internal 
positive and negative calibrators, the 3 reference probes and the control samples. The median 
of the 24 probes for each of 27 healthy control samples was calculated. The mean NanoString 
score of the 27 healthy controls +2SD of the mean was calculated. Scores above this value 
(>2.724) were designated as positive. The list of probes used in NanoString ISG analysis is 
supplied in Table S1. 
 
Online supplemental material 
Table S1 provides additional data on the probes used in the NanoString ISG analysis. Figure 
S1 provides radiological images of COVID-19 in the patients. Figure S2 shows the auto-Ab 
result for lung-targeted auto-Abs (KCNRG and BPIFB1). Figure S3 shows the ISGs used in 
the Nanostring, at the different time-points as well as the neutrophil score.  
 
Table legends 
 
Table 1: Baseline demographic, genetic and clinical characteristics of the 22 APS-
1 patients with SARS-CoV-2 infection included in this study  
AIRE, autoimmune regulator; APS-1 autoimmune polyglandular syndrome type 1; AI, 
adrenal insufficiency; HP, hypoparathyroidism, CMC, chronic mucocutaneous candidiasis; 
HT, hypothyroidism; PA, pernicious anemia; DM, diabetes mellitus; PTH, parathyroid 
hormone; HRT, hormone replacement therapy; NT, not tested; F, female; M, male; IFN, 
interferon.  
 
Table 2: Clinical features of 22 APS-1 patients with SARS-CoV-2 infection  
EF, ejection fraction; DLCO, diffusing capacity for carbon monoxide; LOP/RIT, 
lopinavir/ritonavir; HCQ, hydroxychloroquine; GGO, ground-glass opacities; CRP, C-
reactive protein; AST, aspartate aminotransferase; ALC, absolute lymphocyte count; ECMO, 
extracorporeal membrane oxygenation; GI, gastrointestinal; N/A, not available. *Hypoxemia 
defined as SpO2 <94 mmHg. 
 
Figure legends  
 
Figure 1: APS-1 patients have neutralizing auto-Abs against type I IFNs, the 
titers of which can be decreased by plasmapheresis. (A) Titers of auto-Ab titers against the 
17 type I IFNs in APS-1 patients infected with SARS-CoV-2 (n=8). (B) Neutralization of 
IFN-α2 by various dilutions of auto-Ab-containing serum from APS-1 patients with COVID-
19 (n=5). (C) Plasmapheresis (PE) decreased the titers of type I IFN auto-Abs in one APS-1 
patient (P17) with COVID-19 pneumonia. The titers of auto-Abs against IFN-α2 are shown 
for one of the APS-1 patients treated by plasmapheresis. (D) Plasmapheresis (PE) decreased 
the titers of type I IFN auto-Abs in another APS-1 patient (P18) with COVID-19 pneumonia, 
treated with plasmapheresis, convalescent plasma and IFN-β (as shown with arrows). The 
titers of auto-Abs against IFN-α2 are shown for the APS-1 patients treated by plasmapheresis 
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in the upper panel. In the lower panel, ISG scores -evaluated by Nanostring- show an increase 
after the initiation of treatments. ISG score cut-off for positivity is 2,758.  
 
Figure S1: Imaging of COVID-19 pneumonia in APS-1 patients. (A) Course of 
COVID-19 pneumonia in an APS-1 patient. Bilateral (left>right) ground glass opacities are 
seen on initial chest CT six days after symptom onset (left upper panel). Persistence of 
bilateral ground glass opacities with a worsening of radiographic signs in the left lung base on 
day 10 after symptom onset (right upper panel). Improvement of ground glass opacities on 
days 16 (left lower panel) and 37 (right lower panel) after symptom onset. (B) Coronal chest 
CT angiogram demonstrating non-occlusive segmental pulmonary embolus to the distal 
pulmonary arterial branches of the right lower lobe. (C) Chest CT scan of an APS-1 patient 
showing bilateral alveolo-interstitial lesions of COVID-19 pneumonia.  
 
Figure S2: Analysis of lung-targeting auto-Abs against KCNRG and BPIFB1 in 
APS-1 patients with COVID-19. Auto-Ab titers to KCNRG (A) and BPIFB1 (B) in APS-1 
patients with COVID-19 (n=8). Positive and negative control sample results are also shown. 
 
Figure S3: ISG score and neutrophil score at different time points in an APS-1 
patient, with severe COVID-19, and treated with plasmapheresis, convalescent plasma 
and IFN-β. (A) 24 ISGs are shown at each time point, and (B) 6 neutrophil signature genes 
are shown. ISG score are higher during treatment, while the neutrophile score diminishes.  
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Table 1: Baseline demographic, genetic and clinical characteristics of the 22 APS-1 patients with SARS-CoV-2 infection included in the study 
 
Patient 
# 
Ancestry/residence Age Sex AIRE variants 
IFN-, 
IFN-, 
IFN- 
auto-Ab 
positivity 
Prior non-
infectious 
clinical 
manifestations  
Prior 
infections  
Treatments at the time of 
SARS-CoV-2 infection 
diagnosis 
 
1 European/Italy 32 F R203X/R203X  
IFN- 
and IFN-
 
positive 
AI, HP, 
ectodermal 
dystrophy, 
hypogonadism 
PA, enteropathy 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, iron, magnesium, 
vitamin B12, folic acid, 
cholecalciferol, PTH, HRT, 
mesalasine, pancreatic enzyme 
replacement therapy, rifaximin 
2 European/Scotland 35 F 
L323SfsX51/ 
L323SfsX51 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
gastroparesis 
None 
Hydrocortisone, fludrocortisone, 
estrogen, PTH 
3 European/USA 48 F 
L323SfsX51/ 
S64TfsX71 
IFN-α, 
IFN-, 
and IFN-
ω positive 
AI, HP, HT, 
hypogonadism, 
Sjögren’s 
syndrome 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, levothyroxine, HRT 
4 European/France 21 M R257X/P539L 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, DM, 
HT, asplenia, 
exocrine 
pancreatic 
insufficiency, 
myocarditis 
CMC 
Hydrocortisone, fludrocortisone, 
levothyroxine, insulin, 
fluconazole, 
trimethoprim/sulfamethoxazole, 
pancreatic enzymes, monthly 
IVIg 
 
5 European/Russia  34 M NT 
IFN- 
positive 
AI, HP, 
enteropathy, nail 
dystrophy 
None 
Hydrocortisone, fludrocortisone, 
calcitriol 
 
6 European/Russia 13 F R257X/ R257X NT 
AI, HP, 
autoimmune 
hepatitis, 
enteropathy, 
pancreatitis, 
nephritis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, amlodipine, enalapril, 
rituximab (treatment initiation in 
October 2017 with re-dosing 
every 6 months; last dose 8 
months prior to SARS-CoV-2 
infection diagnosis), monthly 
IVig 
 
7 European/Russia 28 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, 
alopecia, ptosis, 
enamel dysplasia 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, fluconazole 
 
8 European/Russia 32 F R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
enteropathy, 
autoimmune 
hepatitis, 
alopecia, vitiligo, 
asplenia, 
Sjögren’s 
syndrome, PA, 
deep vein 
thrombosis, 
ptosis, enamel 
dysplasia, 
cataract  
CMC, 
pneumonia 
Hydrocortisone, fludrocortisone, 
calcium carbonate, alfacalcidol, 
fluconazole, rivaroxaban 
9 European/Russia 14 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, DM, 
alopecia, enamel 
dysplasia, asthma 
CMC 
Hydrocortisone, fludrocortisone, 
fluconazole  
10 European/Russia 8 F R257X/E298X 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, 
alopecia, PA, 
autoimmune 
hepatitis, 
autoimmune 
encephalitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, fluconazole, monthly 
IVIg 
 
11 European/Russia 28 F R257X/R257X 
IFN- 
and IFN-
 
positive 
HP CMC Alfacalcidol, fluconazole  
12 European/Russia 16 M R257X/R257X 
IFN- 
and IFN-
 
positive 
enamel 
hypoplasia 
CMC Fluconazole 
 
13 European/Russia 20 F R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
HT 
CMC 
Hydrocortisone, fludrocortisone, 
alfacalcidol, levothyroxine, HRT 
14 European/France 31 F NT 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
PA, 
hypopituitarism, 
achalasia  
CMC Hydrocortisone, levothyroxine  
15 European/USA 45 M 
S64TfsX71/ 
L323SfsX51 
IFN- 
and IFN-
 
positive 
AI, HP, HT, end-
stage renal 
disease, alopecia, 
PA, vitiligo, 
enteropathy 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, ruxolitinib 
 
16 European/France 38 F NT IFN- AI, HP, CMC, Hydrocortisone, fludrocortisone, 
and IFN-
 
positive 
myocarditis, PA, 
hypogonadism, 
cutaneous lupus 
urinary 
tract 
infections 
PTH, iron, magnesium, 1-0-HRT, 
perindopril, vitamin C, 
posaconazole 
17 European/Sweden 8 F P538L/P538L 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, vitiligo, 
lupus-like 
systemic 
inflammation 
None 
Hydrocortisone, fludrocortisone, 
alfacalcidol calcium, magnesium 
18 European/France 11 M NT 
IFN- 
and IFN-
 
positive 
AI, HP, HT CMC 
Hydrocortisone, fludrocortisone, 
calcium, levothyroxine, 
tacrolimus 
19 European/England 18 M c.242T>C/C.1265delC 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, DM, 
alopecia, 
hypogonadism 
CMC 
Hydrocortisone, fludrocortisone, 
calcium 
20 European/France 15 F NT 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
retinitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, weekly methotrexate 
21 European/Russia  10 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, 
enteropathy, 
retinitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, calcitriol, fluconazole  
22 European/Russia  30 F R257X/ L323SfsX51 
IFN- 
positive 
AI, HP, 
hypogonadism 
None 
Hydrocortisone, fludrocortisone, 
calcitriol 
 
 
 
 
 
 
 
 
Table 2. Clinical features of 22 APS-1 patients with SARS-CoV-2 infection 
 
Patient 
# 
Days from 
symptom 
onset to 
hospital 
admission 
COVID-19 
severity 
(NIH ordinal 
scale score) 
COVID-19 
complications 
(other than 
hypoxemia-
related) 
Duration 
of 
hospital 
stay 
(days) 
Hypoxemia 
support*  
(nadir SpO2) 
Intubation 
(duration 
in days) 
Laboratory 
abnormalities 
Radiographic 
abnormalities 
Treatments Outcomes 
 
1 4 Critical (7) 
Hypotension 
requiring 
dobutamine/ 
norepinephrine 
infusion; 
pneumococcal 
pneumonia; 
sepsis-induced 
ventricular 
dysfunction 
(EF, 30%); 
Clostridium 
difficile 
infection 
37 
Mechanical 
ventilation  
(N/A) 
6 N/A 
Bilateral, multiple 
GGO  
High-dose 
hydrocortisone, 
LOP/RIT, 
ribavirin, HCQ, 
piperacillin/ 
tazobactam 
Survival; 
low DLCO 
(55%) two 
months 
after 
discharge 
2 8 Critical (7) None 12 
Mechanical 
ventilation  
(N/A) 
5 
CRP, ALC, 
AST 
Bilateral, multiple 
GGO 
High-dose 
hydrocortisone 
Survival 
3 7 Critical (7) None 17 
Mechanical 
ventilation  
(80%) 
11 
CRP, ALC, 
AST, ALT, 
ferritin, 
LDH,  
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
methyl-
prednisolone, 
azithromycin, 
ceftriaxone, 
HCQ 
Survival 
4 4 Mild (4) None 3 No No N/A Bilateral GGO None Survival  
5 10 
Moderate-
severe (5) 
Antibiotic-
associated 
diarrhea 
10 
No 
(93%) 
No 
CRP, ALC, 
LDH, D-
dimer 
Bilateral, multiple 
GGO 
High-dose 
prednisone, 
tocilizumab,  
vancomycin, 
ertapenem, 
levofloxacin, 
HCQ 
Survival  
6 
Not 
hospitalized 
Mild (1) None 0 No No Not tested Not performed None Survival 
 7 3 Critical (8) 
Bacterial 
sepsis 
(Acinetobacter
Klebsiella), 
pneumothorax 
(twice), acute 
renal failure 
(requiring 
hemodialysis) 
47 
Mechanical 
ventilation  
(60%) 
28 
CRP, ALC, 
AST, ALT, 
creatinine,  
D-dimer, 
IL-6  
Bilateral, multiple 
GGO 
High-dose 
prednisone, 
tofacitinib, 
cefepime, 
sulbactam, 
polymixin B, 
linezolid, 
caspofungin 
Death 
8 4 Critical (8) None 15 
Mechanical 
ventilation  
(82%) 
1 N/A 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Death 
9 7 
Moderate-
severe (5) 
None 15 
Nasal cannula 
(86%) 
No CRP, LDH 
Bilateral, multiple 
GGO 
No Survival 
10 
Not 
hospitalized 
Mild (1) None 0 No No Not tested Not performed No Survival 
11 5 Mild (4) None 12 No No ALC Bilateral GGO No Survival 
12 5 Critical (7) None 26 
Mechanical 
ventilation  
(82%) 
N/A 
CRP, ALC,  
LDH, D-
dimer  
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tocilizumab, 
ribavirin, 
azithromycin, 
cefepime, 
vancomycin, 
voriconazole 
Survival 
13 3 Critical (8) None 14 
Mechanical 
ventilation  
(N/A) 
5 N/A N/A 
High-dose 
dexamethasone, 
tocilizumab 
Death 
14 9 Critical (7) 
Bacterial 
pneumonia, 
bacteremia, 
and sepsis 
>60 days 
Mechanical 
ventilation and 
ECMO 
(N/A) 
42 
CRP, 
ferritin, 
ALT,  
AST,  
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Survival, 
tracheostomy 
 
(Klebsiella, 
Serratia, 
Enterobacter, 
E. coli), 
ventricular 
arrhythmia 
D-dimer 
15 4 Moderate (4) 
Pulmonary 
embolism 
18 No No 
CRP, ALC, 
D-dimer 
Bilateral GGO 
High-dose 
hydrocortisone, 
remdesivir, 
azithromycin, 
ceftriaxone, 
apixaban 
Survival  
16 7 Critical (8) 
Bacterial 
pneumonia 
(Enterobacter) 
pneumothorax 
13 
Mechanical 
ventilation  
(60%) 
12 
CRP, ALC, 
AST, ALT, 
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Death  
17 2 Critical (7) 
Transient 
diabetes 
insipidus 
20 
Mechanical 
ventilation  
(80%) 
4 
CRP, AST, 
IL-6 
Bilateral, multiple 
GGO 
High-dose 
betamethasone, 
plasmapheresis 
Survival  
18 2 Critical (7) Hemoptysis 56 
Mechanical 
ventilation  
(87%) 
25 
CRP, 
ferritin, 
ALC, AST,  
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
IFN-, 
convalescent 
plasma, 
plasmapheresis 
Survival  
19 
Not 
hospitalized 
Mild (2) None 0 No No Not tested Not performed 
Prolonged course 
of stress-dose 
steroids 
Survival  
20 5 Mild (4) None 7 No No N/A Bilateral GGO 
IFN-, 
convalescent 
plasma 
Survival  
21 5 
Moderate-
severe (5) 
GI bleeding 21 days 
Nasal cannula 
(87%) 
No 
CRP, ALC, 
LDH,  
D-dimer, 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tocilizumab, 
meropenem, 
fluconazole, IVIg 
Survival  
22 8 
Moderate-
severe (5) 
None 6 
Nasal cannula 
(89%) 
No 
CRP, ALC, 
AST, ALT, 
ferritin 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tofacitinib,  
Survival  
favipiravir, 
amoxicillin-
clavulanic acid, 
IVIg 
 
Table S1. Probes used for NanoString ISG analysis 
Probes of interest  
(n = 24) 
IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1, CMPK2, 
DDX60, EPSTI1, FBXO39, HERC5, HES4, IFI44, IFI6, IFIH1, 
IRF7, LAMP3, LY6E, MX1, NRIR, OAS1, OASL, OTOF, 
SPATS2L 
Reference probes  
(n = 3) 
NRDC, OTUD5, TUBB 
 
+ Neutrophilic score 
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Abstract 
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune 
polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-
Abs), including circulating auto-Abs neutralizing most type-I interferons (IFNs). These auto-
Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 
pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven 
countries, aged between 8 and 48 years and infected with SARS-CoV-2 since February 2020. 
The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω, one had anti-
IFN-β, another anti-IFN-ε, but none had anti-IFN-κ. Strikingly, nineteen patients (86%) were 
hospitalized for COVID-19 pneumonia, including fifteen (68%) admitted to an intensive care 
unit, eleven (50%) who required mechanical ventilation, and four (19%) who died. 
Ambulatory disease in three patients (14%) was possibly accounted for by prior or early 
specific interventions. Pre-existing auto-Abs neutralizing type-I IFNs in APS-1 patients 
confer a very high risk of life-threatening COVID-19 pneumonia at any age.  
 
Short summary (40 words) 
 Patients with autoimmune polyendocrine syndrome type-1 (APS-1) have circulating 
auto-Abs neutralizing most type-I interferons. These auto-Abs can underlie life-threatening 
COVID-19 pneumonia in the general population. We report 22 APS-1 patients infected with 
SARS-CoV-2 including fifteen (68%) who developed life-threatening disease.  
 
Running title (50 characters max) 
Autoimmune polyendocrine syndrome type-1 and COVID-19 
 
Abbreviation list 
AIRE: Auto-immune regulator 
APS-1: Autoimmune polyendocrine syndrome type-1, 
APECED: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, 
IFNs: Interferons, 
MMR: Measles-mumps-rubella,  
CMC: Chronic mucocutaneous candidiasis 
YFV: Yellow fever virus,  
monoclonal antibody (mAb) 
intravenous immunoglobulin (IVIg) 
JAK: Janus Kinase 
ICU: Intensive Care Unit 
ALC: Absolute lymphocyte count,  
AST: Aspartate transaminase 
ECMO: Extracorporeal membrane oxygenation, 
p02: Partial pressure of oxygen,  
CT-scan: Computed tomography scan,  
mmHg: Millimetre of mercury,  
CRP: C-reactive protein, 
LDH: Lactate deshydrogenase, 
 ISG: Interferon stimulated gene 
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Introduction 
Autoimmune polyendocrine syndrome type 1 (APS-1), also known as autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic inborn 
error of immunity typically caused by biallelic deleterious variants of the autoimmune 
regulator gene (AIRE)1-5. Heterozygous variants can also underlie autosomal dominant forms6. 
Patients with APS-1 have defective central T-cell tolerance, leading to the thymic escape of 
auto-reactive T cells and the development, from early childhood, of a broad range of 
autoantibodies (auto-Abs) against various autoantigens, including endocrine and other tissue 
antigens and cytokines7-12. Among these anti-cytokine auto-Abs, neutralizing auto-Abs 
against IL-17A and IL-17F phenocopy inborn errors of IL-17A/F and underlie chronic 
mucocutaneous candidiasis (CMC)13-15. High mucosal concentrations of IFN-γ were also 
proposed to contribute to CMC16. Virtually all patients with APS-1 produce auto-Abs against 
type I IFNs, generally against the 13 individual IFN-α subtypes and IFN-ω11,12,17-19. These 
auto-Abs were long thought to be clinically silent. This was surprising, as these auto-Abs are 
neutralizing and type I IFNs are potent antiviral molecules, acting through both innate 
immunity (via their secretion by plasmacytoid dendritic cells and other leukocytes) and cell-
intrinsic immunity (in most cell types)20-26. Moreover, the essential role of type I IFNs in 
fending off viruses in humans was confirmed by the description of patients with autosomal 
recessive, complete IFNAR1 or IFNAR2 deficiency and adverse reactions to measles-mumps-
rubella (MMR) vaccine or yellow fever virus (YFV-17D) live-attenuated viral vaccine27-29, 
herpes simplex encephalitis30, or critical COVID-19 pneumonia30-32. Nevertheless, the viral 
phenotype of these patients is not as broad as initially predicted, as neatly illustrated by two 
IFNAR1-deficient adults (26 and 38 years old) who had never been hospitalized for severe 
viral disease until they were admitted for critical COVID-19 pneumonia31. 
In this context, we and others recently reported that three unrelated patients with APS-
1 had life-threatening COVID-19 pneumonia 33,34. These cases suggested that the auto-Abs 
neutralizing type I IFN were pathogenic and contributed to the discovery that they can also 
underlie life-threatening COVID-19 pneumonia in previously healthy individuals without 
APS-1, accounting for at least 10% of the cases in an international cohort of patients33. These 
auto-Abs were more frequent in men (95%) than women (5%), and in elderly patients with 
critical COVID-19, half of the patients with auto-Abs being over the age of 65 years33. These 
auto-Abs typically neutralized the 13 individual IFN-α, or IFN-ω, or both, but only rarely 
IFN-β, -κ, and -ε. These findings were replicated in other cohorts35-39. Subjects with inborn 
errors of type I IFN immunity or neutralizing auto-Abs against type I IFN are, thus, at high 
risk of critical COVID-19 pneumonia, with impaired control of viral replication in the first 
few days of SARS-CoV-2 infection resulting in a secondary phase of pulmonary and systemic 
hyperinflammation32. Subjects with such auto-Abs are also at high risk of YFV-17D disease, 
with these antibodies accounting for three of the eight cases studied40. Interestingly, the three 
patients with YFV-17D disease had auto-Abs that neutralized both the 13 IFN-α and IFN-ω, 
and two also had auto-Abs against IFN-β, these proportions being higher than those reported 
for COVID-19 patients. It is unknown whether patients with APS-1 have ever been 
vaccinated with YFV-17D. Following on from the brief description of three APS-1 patients 
with critical COVID-19 pneumonia, we report here the immunological and clinical features of 
22 patients with APS-1 during the course of SARS-CoV-2 infection.   
 
Results 
Baseline characteristics of the patients  
The 22 patients studied were aged 8 to 48 years at the time of infection with SARS-
CoV-2 (median: 24.5 years). Nine were male and 13 were female. Eight were children under 
the age of 16 years (Table 1). All had undergone vaccination according to the schedules in 
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force in their country of origin, including vaccination with the live attenuated MMR, with no 
overt adverse events, between the ages of one to two years. None of the patients had a 
previous history of severe viral infection, and only one had a history of pneumonia. The 22 
patients came from 21 unrelated families (two patients were siblings). The patients originated 
from and lived in England (n=1), France (n=5), Italy (n=1), Russia (n=11), Scotland (n=1), 
Sweden (n=1), and the United States of America (n=2). Twenty-one of the 22 patients had a 
typical clinical diagnosis of APS-1 (i.e., any two of the classic triad of manifestations: 
hypoparathyroidism, adrenal insufficiency, and CMC), with confirmation of the presence of 
homozygous or compound heterozygous loss-of function variants of AIRE in the 17 tested 
patients. One 16-year-old patient with biallelic loss-of-function AIRE mutations (p.R257X) 
presented only CMC. Twenty-one of the 22 patients had a history of severe tissue auto-
immunity, including hypoparathyroidism (n=20), adrenal insufficiency (n=20), hypogonadism 
(n=9), enteropathy (n=9), pernicious anemia (n=6), alopecia (n=6), autoimmune hepatitis 
(n=3), and vitiligo (n=3), and all but four had a history of CMC. One patient was on 
immunosuppressive treatment with the B cell-depleting monoclonal antibody (mAb) 
rituximab and monthly intravenous immunoglobulin (IVIg) substitution, another was on 
treatment with the JAK inhibitor ruxolitinib, a third patients was receiving treatment with the 
calcineurin inhibitor tacrolimus, and another two patients were on monthly IVIg treatment. 
Other treatments included endocrine replacement therapy (hydrocortisone and/or 
fludrocortisone, n=20; levothyroxine, n=5) and antifungal prophylaxis (fluconazole, n=8).  
 
Clinical, radiographic, and laboratory characteristics of COVID-19 infection in 
22 patients with APS-1, in chronological order 
 Patient 1 is a 32-year-old Italian woman with a history of the classic triad 
manifestations, enteropathy and pernicious anemia34. She was diagnosed with bilateral 
COVID-19 pneumonia in February 2020 and hospitalized for 37 days in Northern Italy. She 
developed hypoxemia requiring ICU admission and mechanical ventilation for six days. She 
developed secondary pneumococcal pneumonia and sepsis-induced ventricular dysfunction. 
She was treated with corticosteroids and broad-spectrum antibiotics. Two months after 
discharge from hospital, her pulmonary function was persistently impaired (i.e., diffusing 
capacity for carbon monoxide, 55%).  
Patient 2 is a 35-year-old Scottish woman with a history of hypoparathyroidism, 
adrenal insufficiency and hypogonadism, but not CMC33. She was diagnosed with bilateral 
COVID-19 pneumonia in March 2020 and hospitalized for 12 days. She developed 
hypoxemia and was intubated and mechanically ventilated in the ICU for five days. She 
developed lymphopenia (ALC, 600/mm3) and a mild increase in transaminase levels (AST, 89 
U/L). She was treated with corticosteroids; she recovered and was discharged home.  
Patient 3 is a 48-year-old American woman of Danish ancestry with a history of the 
classic triad manifestations, hypogonadism, hypothyroidism, and Sjögren’s syndrome33. She 
was diagnosed with bilateral COVID-19 pneumonia and hospitalized in March 2020 for 17 
days. She developed hypoxemia and was intubated in the ICU for 11 days. She developed 
lymphopenia (ALC, 650/mm3), an increase in transaminase levels (AST, 1668 U/L), 
hyperferritinemia (14,679 μg/dL), and high D-dimer levels. She was treated with 
corticosteroids and broad-spectrum antibiotics; she recovered and was discharged home. 
Patient 4 is a 21-year-old French man with a history of the classic triad manifestations, 
type 1 diabetes, asplenia, and myocarditis14. He was on monthly IVIg substitution at the time 
of infection. He developed a high fever and mild respiratory symptoms in May 2020. He was 
hospitalized, with radiographic evidence of mild pneumonia not requiring oxygen therapy.  
Patient 5 is a 34-year-old Russian man with a history of hypoparathyroidism, adrenal 
insufficiency, and enteropathy, but no CMC. He was hospitalized for 10 days in January 2021 
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with bilateral COVID-19 pneumonia. He developed hypoxemia requiring oxygen 
supplementation, lymphopenia (ALC, 380/mm3) and an increase in D-dimer levels. He 
received corticosteroids, tocilizumab, and broad-spectrum antibiotics, and made a full 
recovery.  
Patient 6 is a 13-year-old Russian girl with a history of the classic triad manifestations, 
autoimmune hepatitis, and enteropathy. She was diagnosed with COVID-19 infection while 
asymptomatic during a SARS-CoV-2 PCR test performed for screening purposes before a 
routine clinic visit in July 2020. Interestingly, she had been on rituximab since October 2017, 
and was also receiving IVIg substitution (0.5 g/kg monthly).  
Patient 7 was a 28-year-old Russian man with a history of the classic triad 
manifestations, enteropathy, and alopecia, who was hospitalized in the ICU for bilateral 
COVID-19 pneumonia in October 2020. He suffered severe hypoxemia requiring mechanical 
ventilation for four weeks, complicated by secondary bacterial sepsis, acute renal failure 
requiring hemodialysis, and two episodes of pneumothorax. He developed lymphopenia 
(ALC, 100/mm3), high transaminase levels (ALT, 225 U/L), and high D-dimer levels. He was 
treated with broad-spectrum antibiotics, with the initiation of corticosteroids and tofacitinib 
three to eight days after the onset of hypoxemia. He died after 47 days in the hospital. 
Patient 8 was a 32-year-old Russian woman with a history of the classic triad 
manifestations, autoimmune hepatitis, alopecia and a previous episode of pneumonia, which 
is seen in the setting of autoimmune pneumonitis in APS-1 patients41. She was hospitalized in 
the ICU of a hospital for COVID-19 for 15 days in October 2020. She developed severe 
hypoxemia requiring mechanical ventilation, and died of respiratory failure. She was treated 
with corticosteroids from day 13 of hospitalization, two days before her death. 
Patient 9 is a 14-year-old Russian adolescent with a history of CMC, adrenal 
insufficiency, alopecia and type 1 diabetes. He was hospitalized for bilateral COVID-19 
pneumonia for 15 days in October 2020. He developed hypoxemia requiring oxygen 
supplementation by a nasal cannula for six days. He recovered and was discharged home.  
Patient 10 is an eight-year-old Russian girl with a history of the classic triad 
manifestations, enteropathy, autoimmune hepatitis and autoimmune encephalitis. She was 
receiving IVIg substitution (0.5 g/kg monthly) at the time of infection. She was diagnosed 
with asymptomatic COVID-19 following screening by serological SARS-CoV-2 IgG testing 
after her mother was diagnosed with mild COVID-19 infection.  
Patient 11 is a 28-year-old Russian woman with a history of CMC, 
hypoparathyroidism, and enteropathy. She was hospitalized in October 2020 for 12 days for 
bilateral COVID-19 pneumonia not requiring oxygen supplementation. She developed 
lymphopenia (ALC, 190/mm3). She recovered and was discharged home.  
Patient 12 is a 16-year-old Russian man with a history of CMC and enamel 
hypoplasia. He was hospitalized for 26 days in October 2020 for bilateral COVID-19 
pneumonia. He developed hypoxemia requiring ICU admission and mechanical ventilation. 
He developed lymphopenia (ALC, 600/mm3) and his D-dimer levels increased. He was 
treated with corticosteroids, tocilizumab, and broad-spectrum antibiotics. He recovered and 
was discharged home.  
Patient 13 was a 20-year-old Russian woman with a history of the classic triad 
manifestations and hypothyroidism. She was hospitalized for 14 days for COVID-19 
pneumonia. She was already hypoxemic at admission and her hospital course was further 
complicated by worsening hypoxemia, requiring ICU admission and mechanical ventilation 
on day 9 of hospitalization. She was then treated with corticosteroids and tocilizumab, but 
died from respiratory failure five days after intubation.  
Patient 14 is a 31-year-old French woman with a history of the classic triad 
manifestations, hypogonadism, and pernicious anemia. She was hospitalized for more than 60 
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days for COVID-19 pneumonia in November 2020. She developed hypoxemia requiring ICU 
admission, mechanical ventilation, and extracorporeal membrane oxygenation (ECMO). She 
suffered from multiple secondary bacterial infections, including pneumonia, bacteremia, and 
sepsis, and ventricular tachycardia. She developed mild increases in transaminase (AST, 77 
U/L) and D-dimer levels. She was treated with corticosteroids. She survived but required 
tracheostomy and intensive respiratory rehabilitation due to persistent respiratory 
insufficiency.  
Patient 15 is a 45-year-old American man of Danish ancestry, brother of Patient 3, 
with a history of the classic triad manifestations, enteropathy, alopecia, pernicious anemia, 
hypothyroidism, and end-stage renal disease on hemodialysis. He was hospitalized in 
November 2020 as a prophylactic measure, to facilitate close monitoring after his diagnosis 
with COVID-19 at an external facility. He was febrile upon admission, with mild respiratory 
symptoms, no hypoxemia, and bilateral pneumonia on imaging. He was treated with 
remdesivir and corticosteroids, while ruxolitinib was continued to prevent progression to 
hypoxemia and rebound inflammation. His hospital course was complicated by pulmonary 
embolism (Fig. S1B), which was treated with anticoagulation. He recovered without needing 
oxygen supplementation or ICU admission and was discharged home after an 18-day stay in 
hospital.  
Patient 16 was a 38-year-old French woman with a history of the classic triad 
manifestations, hypogonadism, pernicious anemia, myocarditis, and cutaneous lupus. She was 
hospitalized for 13 days in November 2020. She developed hypoxemia requiring ICU 
admission and mechanical ventilation. She developed multiple bacterial superinfections and 
pneumothorax. She was treated with corticosteroids after intubation. She developed 
lymphopenia (ALC, 290/mm3), and her transaminase (AST, 76 U/L) and D-dimer levels 
increased slightly. She died of respiratory failure after 12 days of intubation.  
Patient 17 is an eight-year-old Swedish girl with a history of hypoparathyroidism, 
adrenal insufficiency, and vitiligo, but not CMC. She was hospitalized for bilateral COVID-
19 pneumonia at the end of November 2020. She developed hypoxemia requiring ICU 
admission and mechanical ventilation for four days. She was treated with corticosteroids, 
plasmapheresis, which successfully decreased type I IFN auto-Ab titers (Fig. 1C), and IVIg 
substitution. She recovered and was discharged home after a 20-day stay in hospital.  
Patient 18 is an 11-year-old French boy with the classic triad manifestations and 
hypothyroidism. He was hospitalized for 56 days in December 2020 for bilateral COVID-19 
pneumonia. His course was complicated by hypoxemia requiring ICU admission and 
mechanical ventilation. He developed lymphopenia (ALC, 300/mm3) and increases in D-
dimer and transaminase (AST, 48 U/L) levels. He was receiving tacrolimus before COVID-
19. He was treated with corticosteroids, IFN-β (45 μg, AVONEX, 3 injections), convalescent 
plasma, and plasmapheresis, which decreased type I IFN auto-Ab titers (Fig. 1D).  
Patient 19 is an 18-year-old British man with a history of the classic triad 
manifestations, hypogonadism, type 1 diabetes, and alopecia. He was diagnosed with 
COVID-19 infection at the end of December 2020 after the diagnosis of his parents. He 
developed a high fever and mild cough and was instructed to initiate stress-dose corticosteroid 
treatment and to continue until the symptoms had completely resolved, to prevent secondary 
hyperinflammation. He remained at home without the need for hospitalization and recovered 
after seven days. 
Patient 20 is a 15-year-old French girl with a history of the hypoparathyroidism, 
adrenal insufficiency, and hypogonadism, hypogonadism and retinitis. She had weekly 
methotrexate treatment for her retinitis. She was diagnosed with mild COVID-19 pneumonia 
in early January 2021. She had radiological evidence of bilateral COVID-19 pneumonia (Fig. 
S1C). After multidisciplinary discussion, she was hospitalized for treatment with three 
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injections of IFN-β (45 μg, AVONEX) and convalescent plasma therapy to prevent 
progression to hypoxemic COVID-19 pneumonia. She developed high fever for 72h and 
recovered without requiring oxygen supplementation and was discharged home.  
Patient 21 is a 10-year-old Russian boy with a history of the classic triad 
manifestations, enteropathy, and retinitis. He was hospitalized for 24 days in January 2021 for 
bilateral COVID-19 pneumonia. He developed hypoxemia requiring oxygen supplementation 
by nasal cannula. He developed lymphopenia (ALC, 840/mm3) and his D-dimer levels 
increased. He was treated with corticosteroids, tocilizumab, prophylactic anticoagulation, and 
broad-spectrum antibiotics. He recovered and was discharged home. 
Patient 22 is a 30-year-old Russian woman with a history of hypoparathyroidism, 
adrenal insufficiency, and hypogonadism. She was hospitalized for six days in January 2021 
for COVID-19 pneumonia. She developed hypoxemia requiring oxygen supplementation by a 
nasal cannula. She presented a mild increase in transaminase levels (ALT, 128 U/L). She 
received corticosteroids, tofacitinib, faripiravir, and prophylactic anticoagulation. She 
recovered and was discharged home. 
 
Auto-Abs against type I IFNs in the patients 
All the patients tested (n=21, P6 not tested) had high titers of neutralizing auto-Abs 
against IFN-α2 and/or IFN-ω, and one (P3) also had auto-Abs against IFN-β (Table 1). All 
patients but 2 had been tested for the auto-Abs before COVID-19 pandemic. We also tested 
for the presence of auto-Abs against the 17 individual type I IFNs for all patients for whom 
serum or plasma samples were available. Eight patients were tested for the presence of auto-
Abs against all 13 individual IFN-α and IFN-ω, and they all tested positive (Figure 1A). Only 
one patient had auto-Abs against IFN-β and one other had auto-Abs against IFN-ε while none 
of the patients tested had auto-Abs against IFN-κ. We then confirmed that these auto-Abs had 
neutralizing activity (Fig. 1B), against IFN-α2 and IFN-ω in all patients, and against IFN-β in 
the only patient positive for auto-Abs against this cytokine. We could not test the neutralizing 
activity of the auto-Abs to IFN-ε. The serum and plasma samples from patients without 
detectable auto-Abs against IFN-β did not neutralize the activity of this cytokine. Pre- and 
post-COVID serum samples were available for 4 patients, and we found no significant 
differences in titer or neutralization capacity of anti-IFN auto-Abs before and after SARS-
CoV-2 infection. We also tested for lung-targeted auto-Abs against the lung antigens KCNRG 
and BPIFB1 in 8 patients (5 severe and 3 mild/moderate)41. All examined patients were 
negative for KCNRG auto-Abs but two patients, one with severe (P17) and another with mild 
COVID-19 (P19), tested positive for BPIFB1 auto-Abs (Fig. S2).  
 
Life-threatening COVID-19 pneumonia in 15 APS-1 patients 
All 15 patients with hypoxemic COVID-19 pneumonia had positive SARS-CoV-2 
PCR results. They had a median age of 30 years (range: 8-48 years). Six were male and nine 
were female (Tables 1 and 2). Five were children under the age of 16 years. The patients were 
admitted to hospital between 2 and 10 days after the onset of clinical manifestations (median: 
5 days) and were hospitalized for a median of 16 days (range: 6-50 days). We applied the NIH 
ordinal scale (range: 1-8)42 to assess the severity of COVID-19 in these patients. They were 
found to have a median ordinal scale score of 7 (range: 5-8). The degree of hypoxemia was 
variable, with a median nadir pO2 of 82 mmHg (range: 60-93 mmHg). Eleven patients 
required intubation and mechanical ventilation for a median of six days (range: 1-27 days), 
and one patient required ECMO for 42 days. All patients had a chest CT-scan or X ray 
showing extensive bilateral ground-glass opacities due to severe COVID-19 pneumonia (Fig. 
S1A). Four patients suffered from bacterial superinfections, including ventilator-associated 
pneumonia, bacteremia, and sepsis. Two patients developed pneumothorax requiring chest 
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tube placement, twice in one patient, and ventricular tachycardia and sepsis-induced 
cardiomyopathy occurred in one patient each. One patient was discharged with a 
tracheostomy. All patients had high CRP levels, eight had lymphopenia, seven had high D-
dimer levels, six had high transaminase levels, and four had high ferritin and LDH levels.  
 
Managements of the 15 patients with life threatening COVID-19 
Thirteen patients received high-dose corticosteroids (>0.5 mg/kg prednisone 
equivalent/day) in the form of dexamethasone, betamethasone, hydrocortisone, 
methylprednisolone, or prednisone (Table 2); all 10 patients given corticosteroids within 24 
hours of the onset of hypoxemia survived, whereas all four patients receiving corticosteroids 
later in the course of their hypoxemic disease died (P=0.002; chi-squared test with Yates' 
correction). Six patients received broad-spectrum antibacterial antibiotics and three patients 
received antiviral treatment with faripiravir, ribavirin, or a combination of lopinavir/ritonavir 
with ribavirin. Four patients received anti-IL-6 receptor therapy (tocilizumab) and two 
patients received the JAK-inhibitor tofacitinib. One patient (P20) received convalescent 
plasma (twice, 24 hours apart) and intramuscular recombinant IFN-β (Avonex, 45 μg every 
48 hours, three injections). Plasmapheresis was performed in two patients (daily, five times 
for P17 and six times for P18), resulting in a decrease in type I IFN auto-Ab titers in both 
(Fig. 1C, D). One patient (P18) also received 3 injections of intramuscular IFN-β as well as 
convalescent plasma, after the first three plasmapheresis sessions. We monitored the blood 
interferon stimulated gene (ISG) response in this patient using Nanostring. Interestingly, we 
found a clear increase of ISGs after the initiation of plasmapheresis and IFN-β treatment (Fig. 
1D and S3). Four patients (18%) died from sepsis and/or respiratory failure. All the patients 
who died were adults (aged 20, 28, 32 and 38 years old). The 11 survivors, aged 8 to 48 years, 
have been discharged from hospital, including one patient suffering from chronic respiratory 
failure and still dependent on oxygen therapy at most recent follow-up. 
 
Mild non-hypoxemic COVID-19 infection in seven APS-1 patients and the 
efficacy of early treatment in three of these patients  
Seven of 22 patients (32%) had SARS-CoV-2 infection without developing 
hypoxemia (Tables 1 and 2). The median age of these patients was 18 years (range: 8-45 
years). Three were male and four were female. Three were children under the age of 15 years. 
Interestingly, two of these patients were receiving monthly IVIg therapy at the time of 
infection; one remained asymptomatic and was treated as an outpatient whereas the other was 
hospitalized with a high fever and bilateral pneumonia but did not develop hypoxemia. 
Another patient with asymptomatic infection was receiving IVIg and had also received 
rituximab eight months before the diagnosis of COVID-19. Moreover, an American man on 
ruxolitinib treatment was admitted for prophylactic monitoring when he developed a high 
fever and pneumonia. Treatment with corticosteroids and a 10-day course of remdesivir were 
initiated in this patient, with the aim of preventing progression to hypoxemic COVID-19. In 
addition, a British patient harboring BPIFB1 auto-Abs recovered at home following the early 
initiation and prolonged administration of stress-dose corticosteroid therapy after the 
development of a high fever with symptoms of pneumonia. Finally, a French patient whose 
family was made aware of the risk of severe COVID-19 in APS-1 was hospitalized 
prophylactically two days after symptom onset, while presenting mild radiographic lesions on 
a chest CT scan (Fig. S1C). She was treated with subcutaneous recombinant IFN-β (Avonex, 
45 μg dose every 48 hours, 3 doses) and convalescent plasma therapy for two consecutive 
days, with the goal of preventing progression to hypoxemic COVID-19. She recovered fully 
without the need for oxygen supplementation and was discharged home without sequelae.  
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Pre-existing auto-Abs to type I IFNs underlie life-threatening COVID-19 in APS-
1 patients 
We describe 22 patients with APS-1 from 21 kindreds from seven countries who were 
infected with SARS-CoV-2 between February 2020 and January 2021. Nineteen patients 
(86%) were hospitalized; 15 (68%) developed life-threatening bilateral COVID-19 
pneumonia with hypoxemia requiring admission to an ICU, 11 of whom required mechanical 
ventilation, including five who developed life-threatening secondary complications such as 
sepsis, pneumothorax, arrhythmias and/or pulmonary embolism, and four of whom died 
(18%). As we do not know how many SARS-CoV-2-infected APS-1 patients there are 
worldwide and our series probably reflects an ascertainment bias, we cannot rigorously 
estimate the proportion of life-threatening cases. However, our findings strongly suggest that 
APS-1 patients are at very high risk of critical COVID-19 pneumonia. Our previous report of 
auto-Abs against type I IFNs in at least 10% of patients with critical COVID-19 pneumonia, 
and in none of the subjects with asymptomatic or benign SARS-CoV-2 infection tested33 
further suggests that APS-1 patients are at high risk of developing critical disease because of 
their neutralizing auto-Abs against type I IFNs. This very poor outcome seems to be 
independent of age, sex, European ancestry, and the nature of any other autoimmune 
manifestations. Importantly, our findings confirm that auto-Abs neutralizing type I IFNs 
present before SARS-CoV-2 infection, as opposed to other auto-Abs potentially triggered by 
this infection, confer a very high risk of critical COVID-1931,33,36-39. We also found similar 
levels of auto-Abs prior to and after COVID-19 in the patients tested, further suggesting that 
the infection does not significantly trigger their production.  
 
Vaccination or early treatment to avoid life-threatening COVID-19 pneumonia  
Patients with APS-1 should be prioritized for vaccination against COVID-19. In the 
meantime, all necessary measures should be taken to avoid infection. Our report of seven 
patients with SARS-CoV-2 infection following a mild or moderate, non-hypoxemic course is 
of interest in this respect. Three of these seven patients were on monthly IVIg treatment, 
which may have decreased the pathogenicity of the auto-Abs against type I IFNs or acted 
through other mechanisms. Consistently, one of these patients was also receiving rituximab at 
the time of COVID-19 diagnosis, which may have altered the nature or decreased the titer of 
auto-Abs against type I IFNs. In addition, three patients whose medical teams had been 
informed by us of the risk of critical COVID-19 were treated early in the course of infection, 
one with an early and prolonged course of stress-dose corticosteroids, another by prophylactic 
admission with the administration of corticosteroids and remdesivir, and the third by early 
administration of subcutaneous IFN-β. We thus recommend that infected patients should be 
hospitalized promptly. In patients diagnosed early, ideally before the development of 
pneumonia, several treatments may be considered. First, cocktails of mAb against the SARS-
CoV-2 spike protein may be given to accelerate the decline in viral load43,44; these antibodies 
should be preferred over convalescent plasma, the composition of which is unknown, and 
which may also contain auto-Abs against type I IFNs or other detrimental components and 
have not shown efficacy in severe COVID-19 pneumonia45. Intramuscular or nebulized IFN-
β, or subcutaneous pegylated-IFN-β, may also be considered in patients without auto-Abs 
against IFN-β46, as successfully reported for intramuscular IFN-α2 in patients with inborn 
errors of type I IFN47 and for IFN-β in a patient with incontinentia pigmenti and auto-Abs 
against type I IFNs48. Obviously, the administration of IFN-α2 is not indicated in APS-1 
patients. In patients treated with IFN-β, a monitoring of anti-IFN-β auto-Abs will be 
important. In the small minority of APS-1 patients carrying auto-Abs against IFN-β, 
alternative options could be considered.  
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Rescue treatment in patients with APS-1 and life-threatening COVID-19 
When patients present with hypoxemia in the later phase of COVID-19, the 
administration of mAbs against the SARS-CoV-2 spike protein and of IFN-β should be 
avoided, given the potential risk of worsening the hyperinflammation and hypoxemia49,50. In 
hypoxemic patients, the early initiation of high-dose corticosteroid treatment is crucial, to 
prevent a worsening of lung injury and death, as suggested by the observation that patients 
receiving high-dose corticosteroids at or within 24 hours of the onset of hypoxemia recovered, 
whereas the later initiation of corticosteroids was associated with death 51. Indeed, two 
symptomatic patients without hypoxemic disease who received corticosteroids did not 
progress to severe disease, further suggesting that early corticosteroid treatment might prevent 
or attenuate the secondary hyperinflammatory phase of disease32. The prompt initiation of 
corticosteroid treatment is of particular importance in APS-1 patients with pre-existing 
autoimmune pneumonitis, a frequently overlooked manifestation of APS-1 that affects up to 
~40% of patients41, as the inflammation-prone lung tissue in these patients may confer a 
predisposition to a worsening of lung injury. Two of the eight patients tested here had auto-
Abs against the lung auto-Ab BPIFB1. Such patients are often misdiagnosed as having a prior 
history of reactive airway disease or recurrent pneumonia41. Finally, both in the early phase of 
disease and after the development of COVID-19 pneumonia, plasmapheresis should be 
considered, as it has been safely performed in two APS-1 patients (this report) and four 
patients without APS-138. This procedure can lower the titers of circulating auto-Abs against 
type I IFNs without lowering the titers of anti-viral Abs38, and it may be more beneficial when 
performed early in the course of hospitalization.  
 
 No previous viral disease before severe COVID-19  
 None of the 22 APS-1 patients had previously suffered from severe viral infections, 
consistent with the history of most patients with APS-110. By inference from our recent 
observation that auto-Abs against type I IFNs can underlie life-threatening disease due to the 
YFV-17D live attenuated virus vaccine40, APS-1 patients should not be vaccinated against 
YFV. None of the 22 patients described here reported having been inoculated with the YFV-
17D vaccine. It is striking that these and other APS-1 patients have not been reported to suffer 
from other severe viral infections, including MMR disease and herpes simplex virus 
encephalitis, which have been reported in patients with IFNAR1 or IFNAR2 deficiency27-30. 
This may reflect the residual activity of some of the 17 type I IFNs, including IFN-β in 
particular, or that at the age of vaccination or HSV-1 infection, the auto-Abs were not yet 
present, or not as potent, or did not target all the type I IFNs neutralized in older APS-1 
patients. There is, nevertheless, one case report of an APS-1 patient suffering from recurrent 
cutaneous HSV-1 infection52. The paucity of viral infections in patients with inherited 
IFNAR1 or IFNAR2 deficiency is, itself, intriguing27,28,30,32,53. Careful retrospective and 
prospective studies of viral infections and viral diseases in APS-1 patients are therefore 
warranted. More generally, a careful study of viral infections and viral diseases in patients 
with inherited IFNAR1 or IFNAR2 deficiency, and in patients with auto-Abs against type I 
IFNs, regardless of their etiology, is also warranted.  
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Methods  
Patients and study approval 
Written informed consent was obtained from patients or their parents in the country in which 
they were followed, in accordance with local regulations. The study was approved by the 
institutional review boards of The Rockefeller University and Institut National de la Santé et 
de la Recherche Médicale (INSERM), the NIAID/NIH, the Endocrinology Research Center 
of Russia, and the University of Gothenburg, Sweden. Experiments were conducted in the 
United States of America and France, in accordance with local regulations and with the 
approval of the institutional review boards of The Rockefeller University, NIAID/NIH and 
INSERM. Anonymized samples were studied at the NIAID under non-human subject research 
conditions; no additional IRB consent was required at the NIH. APS-1 patients gave consent 
under IRB-approved protocols 11-I-0187 (clinicaltrials.gov NCT01386437) at the 
NIAID/NIH, study no 779-11. The Swedish patient was enrolled in study no 779-11, 
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approved by the Central Ethical Review Board at the University of Gothenburg. The study 
has been approved by the local ethics committee at Endocrinology Research Center of Russia 
(Protocol №11 from 23.10.2013) and all patients or their parents or guardians singed the 
informed consent. 
 
Detection of anti-cytokine auto-Abs using a cell-based assay 
All Russian patients were tested for neutralizing auto-Abs against IFN-α2 and/or IFN-ω using 
a cell-based assay as previously described12,54.  
 
Detection of anti-cytokine auto-Abs in a multiplex particle-based assay  
Serum/plasma samples were screened for auto-Abs against IFN-α2 and IFN-ω targets in a 
multiplex particle-based assay, in which magnetic beads with differential fluorescence were 
covalently coupled to recombinant human proteins (2.5 µg/reaction). Beads were combined 
and incubated with 1:100 diluted serum/plasma samples for 30 minutes. Each sample was 
tested once. The beads were then washed and incubated with PE-labeled goat anti-human IgG 
antibody (1 µg/mL) for 30 minutes. They were washed again and used in a multiplex assay 
run on a BioPlex X200 instrument. Patients with a fluorescence intensity (FI) > 1500 for IFN-
α2 or IFN-β, or > 1000 for IFN-ω were tested for blocking activity. 
 
Enzyme-linked immunosorbent assays (ELISA) for anti-cytokine auto-Abs 
ELISA was performed as previously described33. In brief, 96-well ELISA plates (MaxiSorp; 
Thermo Fisher Scientific) were coated by incubation overnight at 4°C with 2 μg/mL rhIFN-α, 
and rhIFN-ω (R&D Systems). Plates were then washed (PBS/0.005% Tween), blocked by 
incubation with 5% nonfat milk powder in the same buffer, washed, and incubated with 1:50 
dilutions of plasma from the patients or controls for 2 h at room temperature (or with specific 
mAbs as positive controls). Each sample was tested once. Plates were thoroughly washed. 
Horseradish peroxidase (HRP)–conjugated Fc-specific IgG fractions from polyclonal goat 
antiserum against human IgG or IgA (Nordic Immunological Laboratories) were added to a 
final concentration of 2 μg/mL. Plates were incubated for 1 h at room temperature and 
washed. Substrate was added and the optical density (OD) was measured. A similar protocol 
was used to test for antibodies against 12 subtypes of IFN-α, except that the plates were 
coated with cytokines from PBL Assay Science (catalog #11002-1).  
 
Functional evaluation of anti-cytokine auto-Abs 
The blocking activity of auto-Abs against IFN-α2 and IFN-ω was assessed by evaluating 
STAT1 phosphorylation in healthy control cells following stimulation with the appropriate 
cytokines in the presence of 10% serum/plasma from a healthy control or a patient. Surface-
stained healthy control PBMCs (350,000/reaction) were cultured in serum-free RPMI medium 
supplemented with 10% healthy control or patient serum/plasma and were either left 
unstimulated or were stimulated with IFN-α2 and IFN-ω (10 ng/mL) for 15 minutes at 37°C. 
Each sample was tested once. Cells were fixed, permeabilized, and stained for intranuclear 
phospho-STAT1 (Y701). Cells were acquired on a BD LSRFortessa cytometer with gating on 
CD14+ monocytes and analyzed with FlowJo software. 
 
Luciferase immunoprecipitation systems (LIPS) assay for lung-targeted auto-Abs 
We used the LIPS immunoassay to detect auto-Ab immunoreactivity against the lung 
targeting the potassium regulator KCNRG and bactericidal/permeability-increasing fold-
containing B1 (BPIFB1) in APS-1 patient sera. Seropositivity was defined as a value greater 
than the mean for healthy donors plus three standard deviations, as previously described41. 
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IFN score55 
Total RNA was extracted from whole blood with a PAXgene (PreAnalytix) RNA isolation 
kit. RNA concentration was assessed with a spectrophotometer (FLUOstar Omega, Labtech). 
Analysis of 24 genes and 3 housekeeping genes was conducted using the NanoString 
customer designed CodeSets according to the manufacturer’s recommendations (NanoString 
Technologies, Seattle, WA). Agilent Tapestation was used to assess the quality of the RNA. 
100ng of total RNA was loaded for each sample. Data were processed with nSolver software 
(NanoString Technologies Seattle, WA). The data was normalized relative to the internal 
positive and negative calibrators, the 3 reference probes and the control samples. The median 
of the 24 probes for each of 27 healthy control samples was calculated. The mean NanoString 
score of the 27 healthy controls +2SD of the mean was calculated. Scores above this value 
(>2.724) were designated as positive. The list of probes used in NanoString ISG analysis is 
supplied in Table S1. 
 
Online supplemental material 
Table S1 provides additional data on the probes used in the NanoString ISG analysis. Figure 
S1 provides radiological images of COVID-19 in the patients. Figure S2 shows the auto-Ab 
result for lung-targeted auto-Abs (KCNRG and BPIFB1). Figure S3 shows the ISGs used in 
the Nanostring, at the different time-points as well as the neutrophil score.  
 
Table legends 
 
Table 1: Baseline demographic, genetic and clinical characteristics of the 22 APS-
1 patients with SARS-CoV-2 infection included in this study  
AIRE, autoimmune regulator; APS-1 autoimmune polyglandular syndrome type 1; AI, 
adrenal insufficiency; HP, hypoparathyroidism, CMC, chronic mucocutaneous candidiasis; 
HT, hypothyroidism; PA, pernicious anemia; DM, diabetes mellitus; PTH, parathyroid 
hormone; HRT, hormone replacement therapy; NT, not tested; F, female; M, male; IFN, 
interferon.  
 
Table 2: Clinical features of 22 APS-1 patients with SARS-CoV-2 infection  
EF, ejection fraction; DLCO, diffusing capacity for carbon monoxide; LOP/RIT, 
lopinavir/ritonavir; HCQ, hydroxychloroquine; GGO, ground-glass opacities; CRP, C-
reactive protein; AST, aspartate aminotransferase; ALC, absolute lymphocyte count; ECMO, 
extracorporeal membrane oxygenation; GI, gastrointestinal; N/A, not available. *Hypoxemia 
defined as SpO2 <94 mmHg. 
 
Figure legends  
 
Figure 1: APS-1 patients have neutralizing auto-Abs against type I IFNs, the 
titers of which can be decreased by plasmapheresis. (A) Titers of auto-Ab titers against the 
17 type I IFNs in APS-1 patients infected with SARS-CoV-2 (n=8). (B) Neutralization of 
IFN-α2 by various dilutions of auto-Ab-containing serum from APS-1 patients with COVID-
19 (n=5). (C) Plasmapheresis (PE) decreased the titers of type I IFN auto-Abs in one APS-1 
patient (P17) with COVID-19 pneumonia. The titers of auto-Abs against IFN-α2 are shown 
for one of the APS-1 patients treated by plasmapheresis. (D) Plasmapheresis (PE) decreased 
the titers of type I IFN auto-Abs in another APS-1 patient (P18) with COVID-19 pneumonia, 
treated with plasmapheresis, convalescent plasma and IFN-β (as shown with arrows). The 
titers of auto-Abs against IFN-α2 are shown for the APS-1 patients treated by plasmapheresis 
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in the upper panel. In the lower panel, ISG scores -evaluated by Nanostring- show an increase 
after the initiation of treatments. ISG score cut-off for positivity is 2,758.  
 
Figure S1: Imaging of COVID-19 pneumonia in APS-1 patients. (A) Course of 
COVID-19 pneumonia in an APS-1 patient. Bilateral (left>right) ground glass opacities are 
seen on initial chest CT six days after symptom onset (left upper panel). Persistence of 
bilateral ground glass opacities with a worsening of radiographic signs in the left lung base on 
day 10 after symptom onset (right upper panel). Improvement of ground glass opacities on 
days 16 (left lower panel) and 37 (right lower panel) after symptom onset. (B) Coronal chest 
CT angiogram demonstrating non-occlusive segmental pulmonary embolus to the distal 
pulmonary arterial branches of the right lower lobe. (C) Chest CT scan of an APS-1 patient 
showing bilateral alveolo-interstitial lesions of COVID-19 pneumonia.  
 
Figure S2: Analysis of lung-targeting auto-Abs against KCNRG and BPIFB1 in 
APS-1 patients with COVID-19. Auto-Ab titers to KCNRG (A) and BPIFB1 (B) in APS-1 
patients with COVID-19 (n=8). Positive and negative control sample results are also shown. 
 
Figure S3: ISG score and neutrophil score at different time points in an APS-1 
patient, with severe COVID-19, and treated with plasmapheresis, convalescent plasma 
and IFN-β. (A) 24 ISGs are shown at each time point, and (B) 6 neutrophil signature genes 
are shown. ISG score are higher during treatment, while the neutrophile score diminishes.  
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Table 1: Baseline demographic, genetic and clinical characteristics of the 22 APS-1 patients with SARS-CoV-2 infection included in the study 
 
Patient 
# 
Ancestry/residence Age Sex AIRE variants 
IFN-, 
IFN-, 
IFN- 
auto-Ab 
positivity 
Prior non-
infectious 
clinical 
manifestations  
Prior 
infections  
Treatments at the time of 
SARS-CoV-2 infection 
diagnosis 
 
1 European/Italy 32 F R203X/R203X  
IFN- 
and IFN-
 
positive 
AI, HP, 
ectodermal 
dystrophy, 
hypogonadism 
PA, enteropathy 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, iron, magnesium, 
vitamin B12, folic acid, 
cholecalciferol, PTH, HRT, 
mesalasine, pancreatic enzyme 
replacement therapy, rifaximin 
2 European/Scotland 35 F 
L323SfsX51/ 
L323SfsX51 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
gastroparesis 
None 
Hydrocortisone, fludrocortisone, 
estrogen, PTH 
3 European/USA 48 F 
L323SfsX51/ 
S64TfsX71 
IFN-α, 
IFN-, 
and IFN-
ω positive 
AI, HP, HT, 
hypogonadism, 
Sjögren’s 
syndrome 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, levothyroxine, HRT 
4 European/France 21 M R257X/P539L 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, DM, 
HT, asplenia, 
exocrine 
pancreatic 
insufficiency, 
myocarditis 
CMC 
Hydrocortisone, fludrocortisone, 
levothyroxine, insulin, 
fluconazole, 
trimethoprim/sulfamethoxazole, 
pancreatic enzymes, monthly 
IVIg 
 
5 European/Russia  34 M NT 
IFN- 
positive 
AI, HP, 
enteropathy, nail 
dystrophy 
None 
Hydrocortisone, fludrocortisone, 
calcitriol 
 
6 European/Russia 13 F R257X/ R257X NT 
AI, HP, 
autoimmune 
hepatitis, 
enteropathy, 
pancreatitis, 
nephritis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, amlodipine, enalapril, 
rituximab (treatment initiation in 
October 2017 with re-dosing 
every 6 months; last dose 8 
months prior to SARS-CoV-2 
infection diagnosis), monthly 
IVig 
 
7 European/Russia 28 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, 
alopecia, ptosis, 
enamel dysplasia 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, fluconazole 
 
8 European/Russia 32 F R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
enteropathy, 
autoimmune 
hepatitis, 
alopecia, vitiligo, 
asplenia, 
Sjögren’s 
syndrome, PA, 
deep vein 
thrombosis, 
ptosis, enamel 
dysplasia, 
cataract  
CMC, 
pneumonia 
Hydrocortisone, fludrocortisone, 
calcium carbonate, alfacalcidol, 
fluconazole, rivaroxaban 
9 European/Russia 14 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, DM, 
alopecia, enamel 
dysplasia, asthma 
CMC 
Hydrocortisone, fludrocortisone, 
fluconazole  
10 European/Russia 8 F R257X/E298X 
IFN- 
and IFN-
 
positive 
AI, HP, 
enteropathy, 
alopecia, PA, 
autoimmune 
hepatitis, 
autoimmune 
encephalitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcitriol, fluconazole, monthly 
IVIg 
 
11 European/Russia 28 F R257X/R257X 
IFN- 
and IFN-
 
positive 
HP CMC Alfacalcidol, fluconazole  
12 European/Russia 16 M R257X/R257X 
IFN- 
and IFN-
 
positive 
enamel 
hypoplasia 
CMC Fluconazole 
 
13 European/Russia 20 F R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
HT 
CMC 
Hydrocortisone, fludrocortisone, 
alfacalcidol, levothyroxine, HRT 
14 European/France 31 F NT 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
PA, 
hypopituitarism, 
achalasia  
CMC Hydrocortisone, levothyroxine  
15 European/USA 45 M 
S64TfsX71/ 
L323SfsX51 
IFN- 
and IFN-
 
positive 
AI, HP, HT, end-
stage renal 
disease, alopecia, 
PA, vitiligo, 
enteropathy 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, ruxolitinib 
 
16 European/France 38 F NT IFN- AI, HP, CMC, Hydrocortisone, fludrocortisone, 
and IFN-
 
positive 
myocarditis, PA, 
hypogonadism, 
cutaneous lupus 
urinary 
tract 
infections 
PTH, iron, magnesium, 1-0-HRT, 
perindopril, vitamin C, 
posaconazole 
17 European/Sweden 8 F P538L/P538L 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, vitiligo, 
lupus-like 
systemic 
inflammation 
None 
Hydrocortisone, fludrocortisone, 
alfacalcidol calcium, magnesium 
18 European/France 11 M NT 
IFN- 
and IFN-
 
positive 
AI, HP, HT CMC 
Hydrocortisone, fludrocortisone, 
calcium, levothyroxine, 
tacrolimus 
19 European/England 18 M c.242T>C/C.1265delC 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, DM, 
alopecia, 
hypogonadism 
CMC 
Hydrocortisone, fludrocortisone, 
calcium 
20 European/France 15 F NT 
IFN- 
and IFN-
 
positive 
AI, HP, 
hypogonadism, 
retinitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, weekly methotrexate 
21 European/Russia  10 M R257X/R257X 
IFN- 
and IFN-
 
positive 
AI, HP, urticarial 
eruption, 
enteropathy, 
retinitis 
CMC 
Hydrocortisone, fludrocortisone, 
calcium, calcitriol, fluconazole  
22 European/Russia  30 F R257X/ L323SfsX51 
IFN- 
positive 
AI, HP, 
hypogonadism 
None 
Hydrocortisone, fludrocortisone, 
calcitriol 
 
 
 
 
 
 
 
 
Table 2. Clinical features of 22 APS-1 patients with SARS-CoV-2 infection 
 
Patient 
# 
Days from 
symptom 
onset to 
hospital 
admission 
COVID-19 
severity 
(NIH ordinal 
scale score) 
COVID-19 
complications 
(other than 
hypoxemia-
related) 
Duration 
of 
hospital 
stay 
(days) 
Hypoxemia 
support*  
(nadir SpO2) 
Intubation 
(duration 
in days) 
Laboratory 
abnormalities 
Radiographic 
abnormalities 
Treatments Outcomes 
 
1 4 Critical (7) 
Hypotension 
requiring 
dobutamine/ 
norepinephrine 
infusion; 
pneumococcal 
pneumonia; 
sepsis-induced 
ventricular 
dysfunction 
(EF, 30%); 
Clostridium 
difficile 
infection 
37 
Mechanical 
ventilation  
(N/A) 
6 N/A 
Bilateral, multiple 
GGO  
High-dose 
hydrocortisone, 
LOP/RIT, 
ribavirin, HCQ, 
piperacillin/ 
tazobactam 
Survival; 
low DLCO 
(55%) two 
months 
after 
discharge 
2 8 Critical (7) None 12 
Mechanical 
ventilation  
(N/A) 
5 
CRP, ALC, 
AST 
Bilateral, multiple 
GGO 
High-dose 
hydrocortisone 
Survival 
3 7 Critical (7) None 17 
Mechanical 
ventilation  
(80%) 
11 
CRP, ALC, 
AST, ALT, 
ferritin, 
LDH,  
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
methyl-
prednisolone, 
azithromycin, 
ceftriaxone, 
HCQ 
Survival 
4 4 Mild (4) None 3 No No N/A Bilateral GGO None Survival  
5 10 
Moderate-
severe (5) 
Antibiotic-
associated 
diarrhea 
10 
No 
(93%) 
No 
CRP, ALC, 
LDH, D-
dimer 
Bilateral, multiple 
GGO 
High-dose 
prednisone, 
tocilizumab,  
vancomycin, 
ertapenem, 
levofloxacin, 
HCQ 
Survival  
6 
Not 
hospitalized 
Mild (1) None 0 No No Not tested Not performed None Survival 
 7 3 Critical (8) 
Bacterial 
sepsis 
(Acinetobacter
Klebsiella), 
pneumothorax 
(twice), acute 
renal failure 
(requiring 
hemodialysis) 
47 
Mechanical 
ventilation  
(60%) 
28 
CRP, ALC, 
AST, ALT, 
creatinine,  
D-dimer, 
IL-6  
Bilateral, multiple 
GGO 
High-dose 
prednisone, 
tofacitinib, 
cefepime, 
sulbactam, 
polymixin B, 
linezolid, 
caspofungin 
Death 
8 4 Critical (8) None 15 
Mechanical 
ventilation  
(82%) 
1 N/A 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Death 
9 7 
Moderate-
severe (5) 
None 15 
Nasal cannula 
(86%) 
No CRP, LDH 
Bilateral, multiple 
GGO 
No Survival 
10 
Not 
hospitalized 
Mild (1) None 0 No No Not tested Not performed No Survival 
11 5 Mild (4) None 12 No No ALC Bilateral GGO No Survival 
12 5 Critical (7) None 26 
Mechanical 
ventilation  
(82%) 
N/A 
CRP, ALC,  
LDH, D-
dimer  
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tocilizumab, 
ribavirin, 
azithromycin, 
cefepime, 
vancomycin, 
voriconazole 
Survival 
13 3 Critical (8) None 14 
Mechanical 
ventilation  
(N/A) 
5 N/A N/A 
High-dose 
dexamethasone, 
tocilizumab 
Death 
14 9 Critical (7) 
Bacterial 
pneumonia, 
bacteremia, 
and sepsis 
>60 days 
Mechanical 
ventilation and 
ECMO 
(N/A) 
42 
CRP, 
ferritin, 
ALT,  
AST,  
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Survival, 
tracheostomy 
 
(Klebsiella, 
Serratia, 
Enterobacter, 
E. coli), 
ventricular 
arrhythmia 
D-dimer 
15 4 Moderate (4) 
Pulmonary 
embolism 
18 No No 
CRP, ALC, 
D-dimer 
Bilateral GGO 
High-dose 
hydrocortisone, 
remdesivir, 
azithromycin, 
ceftriaxone, 
apixaban 
Survival  
16 7 Critical (8) 
Bacterial 
pneumonia 
(Enterobacter) 
pneumothorax 
13 
Mechanical 
ventilation  
(60%) 
12 
CRP, ALC, 
AST, ALT, 
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone 
Death  
17 2 Critical (7) 
Transient 
diabetes 
insipidus 
20 
Mechanical 
ventilation  
(80%) 
4 
CRP, AST, 
IL-6 
Bilateral, multiple 
GGO 
High-dose 
betamethasone, 
plasmapheresis 
Survival  
18 2 Critical (7) Hemoptysis 56 
Mechanical 
ventilation  
(87%) 
25 
CRP, 
ferritin, 
ALC, AST,  
D-dimer 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
IFN-, 
convalescent 
plasma, 
plasmapheresis 
Survival  
19 
Not 
hospitalized 
Mild (2) None 0 No No Not tested Not performed 
Prolonged course 
of stress-dose 
steroids 
Survival  
20 5 Mild (4) None 7 No No N/A Bilateral GGO 
IFN-, 
convalescent 
plasma 
Survival  
21 5 
Moderate-
severe (5) 
GI bleeding 21 days 
Nasal cannula 
(87%) 
No 
CRP, ALC, 
LDH,  
D-dimer, 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tocilizumab, 
meropenem, 
fluconazole, IVIg 
Survival  
22 8 
Moderate-
severe (5) 
None 6 
Nasal cannula 
(89%) 
No 
CRP, ALC, 
AST, ALT, 
ferritin 
Bilateral, multiple 
GGO 
High-dose 
dexamethasone, 
tofacitinib,  
Survival  
favipiravir, 
amoxicillin-
clavulanic acid, 
IVIg 
 
